Journal Article
. 2010 Feb; 107(9):4275-80.
doi: 10.1073/pnas.0915174107.

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

Michael A Curran 1 Welby Montalvo  Hideo Yagita  James P Allison  
  • PMID: 20160101
  •     28 References
  •     763 citations


Vaccination with irradiated B16 melanoma cells expressing either GM-CSF (Gvax) or Flt3-ligand (Fvax) combined with antibody blockade of the negative T-cell costimulatory receptor cytotoxic T-lymphocyte antigen-4 (CTLA-4) promotes rejection of preimplanted tumors. Despite CTLA-4 blockade, T-cell proliferation and cytokine production can be inhibited by the interaction of programmed death-1 (PD-1) with its ligands PD-L1 and PD-L2 or by the interaction of PD-L1 with B7-1. Here, we show that the combination of CTLA-4 and PD-1 blockade is more than twice as effective as either alone in promoting the rejection of B16 melanomas in conjunction with Fvax. Adding alphaPD-L1 to this regimen results in rejection of 65% of preimplanted tumors vs. 10% with CTLA-4 blockade alone. Combination PD-1 and CTLA-4 blockade increases effector T-cell (Teff) infiltration, resulting in highly advantageous Teff-to-regulatory T-cell ratios with the tumor. The fraction of tumor-infiltrating Teffs expressing CTLA-4 and PD-1 increases, reflecting the proliferation and accumulation of cells that would otherwise be anergized. Combination blockade also synergistically increases Teff-to-myeloid-derived suppressor cell ratios within B16 melanomas. IFN-gamma production increases in both the tumor and vaccine draining lymph nodes, as does the frequency of IFN-gamma/TNF-alpha double-producing CD8(+) T cells within the tumor. These results suggest that combination blockade of the PD-1/PD-L1- and CTLA-4-negative costimulatory pathways allows tumor-specific T cells that would otherwise be inactivated to continue to expand and carry out effector functions, thereby shifting the tumor microenvironment from suppressive to inflammatory.

Costimulation via OX40L expressed by B cells is sufficient to determine the extent of primary CD4 cell expansion and Th2 cytokine secretion in vivo.
Phyllis-Jean Linton, Beverly Bautista, +5 authors, Linda M Bradley.
J Exp Med, 2003 Apr 02; 197(7). PMID: 12668647    Free PMC article.
Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4.
E A Tivol, F Borriello, +3 authors, A H Sharpe.
Immunity, 1995 Nov 01; 3(5). PMID: 7584144
Highly Cited.
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.
Wenshi Wang, Roy Lau, +3 authors, Jeffrey Weber.
Int Immunol, 2009 Aug 05; 21(9). PMID: 19651643    Free PMC article.
Highly Cited.
Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
A van Elsas, A A Hurwitz, J P Allison.
J Exp Med, 1999 Aug 03; 190(3). PMID: 10430624    Free PMC article.
Highly Cited.
Myeloid-derived suppressor cells as regulators of the immune system.
Dmitry I Gabrilovich, Srinivas Nagaraj.
Nat Rev Immunol, 2009 Feb 07; 9(3). PMID: 19197294    Free PMC article.
Highly Cited. Review.
Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor.
H Nishimura, M Nose, +2 authors, T Honjo.
Immunity, 1999 Sep 15; 11(2). PMID: 10485649
Highly Cited.
Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression.
P Zhang, F Gao, +5 authors, L Zhang.
Scand J Immunol, 2007 Sep 14; 66(4). PMID: 17850588
CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion.
Ann E Herman, Gordon J Freeman, Diane Mathis, Christophe Benoist.
J Exp Med, 2004 Jun 09; 199(11). PMID: 15184501    Free PMC article.
Highly Cited.
Tumor vaccines expressing flt3 ligand synergize with ctla-4 blockade to reject preimplanted tumors.
Michael A Curran, James P Allison.
Cancer Res, 2009 Sep 10; 69(19). PMID: 19738077    Free PMC article.
Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.
Tomohide Yamazaki, Hisaya Akiba, +3 authors, Ko Okumura.
J Immunol, 2005 Jul 22; 175(3). PMID: 16034097
TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells.
Song Guo Zheng, Ju Hua Wang, +3 authors, David A Horwitz.
J Immunol, 2006 Mar 07; 176(6). PMID: 16517699
Highly Cited.
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal.
Brian T Fife, Kristen E Pauken, +6 authors, Jeffrey A Bluestone.
Nat Immunol, 2009 Sep 29; 10(11). PMID: 19783989    Free PMC article.
Highly Cited.
Characterization of mouse CD4 T cell subsets defined by expression of KLRG1.
Niklas Beyersdorf, Xin Ding, Julia K Tietze, Thomas Hanke.
Eur J Immunol, 2007 Nov 24; 37(12). PMID: 18034419
Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies.
Karl S Peggs, Sergio A Quezada, +2 authors, James P Allison.
J Exp Med, 2009 Jul 08; 206(8). PMID: 19581407    Free PMC article.
Highly Cited.
Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation.
P S Linsley, W Brady, +3 authors, J A Ledbetter.
J Exp Med, 1991 Mar 01; 173(3). PMID: 1847722    Free PMC article.
Highly Cited.
MFG-E8-mediated uptake of apoptotic cells by APCs links the pro- and antiinflammatory activities of GM-CSF.
Masahisa Jinushi, Yukoh Nakazaki, +3 authors, Glenn Dranoff.
J Clin Invest, 2007 Jun 09; 117(7). PMID: 17557120    Free PMC article.
PD-1 and PD-1 ligands: from discovery to clinical application.
Taku Okazaki, Tasuku Honjo.
Int Immunol, 2007 Jul 04; 19(7). PMID: 17606980
Highly Cited. Review.
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
Karl S Peggs, Sergio A Quezada, James P Allison.
Immunol Rev, 2008 Sep 02; 224. PMID: 18759925
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.
Yoshiko Iwai, Masayoshi Ishida, +3 authors, Nagahiro Minato.
Proc Natl Acad Sci U S A, 2002 Sep 10; 99(19). PMID: 12218188    Free PMC article.
Highly Cited.
Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade.
Nobuhiro Nakamoto, Hyosun Cho, +8 authors, Kyong-Mi Chang.
PLoS Pathog, 2009 Feb 28; 5(2). PMID: 19247441    Free PMC article.
Highly Cited.
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
N Mach, S Gillessen, +3 authors, G Dranoff.
Cancer Res, 2000 Jun 24; 60(12). PMID: 10866317
Highly Cited.
The reverse stop-signal model for CTLA4 function.
Christopher E Rudd.
Nat Rev Immunol, 2008 Jan 26; 8(2). PMID: 18219311
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
Manish J Butte, Mary E Keir, +2 authors, Gordon J Freeman.
Immunity, 2007 Jul 17; 27(1). PMID: 17629517    Free PMC article.
Highly Cited.
Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells.
Yu Liu, Yinyan Yu, +6 authors, Rongcun Yang.
Cancer Immunol Immunother, 2008 Oct 02; 58(5). PMID: 18828017
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.
Richard V Parry, Jens M Chemnitz, +6 authors, James L Riley.
Mol Cell Biol, 2005 Oct 18; 25(21). PMID: 16227604    Free PMC article.
Highly Cited.
Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies.
Raanan Berger, Rinat Rotem-Yehudar, +6 authors, Arnon Nagler.
Clin Cancer Res, 2008 May 17; 14(10). PMID: 18483370
Highly Cited.
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.
Sergio A Quezada, Karl S Peggs, Michael A Curran, James P Allison.
J Clin Invest, 2006 Jun 17; 116(7). PMID: 16778987    Free PMC article.
Highly Cited.
Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Betty Li, Melinda VanRoey, +3 authors, Karin Jooss.
Clin Cancer Res, 2009 Feb 12; 15(5). PMID: 19208793
Dendritic cell subsets as vectors and targets for improved cancer therapy.
Karolina Palucka, Hideki Ueno, +2 authors, Jacques Banchereau.
Curr Top Microbiol Immunol, 2010 May 22; 344. PMID: 20490776    Free PMC article.
Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.
Qing Zhou, Meghan E Munger, +11 authors, Bruce R Blazar.
Blood, 2010 Jun 24; 116(14). PMID: 20570856    Free PMC article.
Highly Cited.
Immune regulatory antibodies: are they the next advance?
Jedd D Wolchok, Arvin S Yang, Jeffrey S Weber.
Cancer J, 2010 Aug 10; 16(4). PMID: 20693841    Free PMC article.
Dendritic cells: are they clinically relevant?
Karolina Palucka, Hideki Ueno, +2 authors, Jacques Banchereau.
Cancer J, 2010 Aug 10; 16(4). PMID: 20693842    Free PMC article.
Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.
Ping Yu, Jason C Steel, +2 authors, Thomas A Waldmann.
Clin Cancer Res, 2010 Oct 07; 16(24). PMID: 20924130    Free PMC article.
T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics.
Yael S Barach, Jun Sik Lee, Xingxing Zang.
Trends Mol Med, 2010 Oct 26; 17(1). PMID: 20971039    Free PMC article.
Hepatitis B e-antigen persistency is associated with the properties of HBV-specific CD8 T cells in CHB patients.
Guoping Peng, Benyan Luo, +4 authors, Zhi Chen.
J Clin Immunol, 2010 Dec 02; 31(2). PMID: 21120686
Dendritic cells and immunity against cancer.
K Palucka, H Ueno, J Fay, J Banchereau.
J Intern Med, 2010 Dec 17; 269(1). PMID: 21158979    Free PMC article.
Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
Kevin Durgan, Mohamed Ali, Paul Warner, Yvette E Latchman.
Cancer Immunol Immunother, 2011 Jan 18; 60(4). PMID: 21240487    Free PMC article.
Lentiviral vectors for induction of self-differentiation and conditional ablation of dendritic cells.
M Pincha, G Salguero, +10 authors, R Stripecke.
Gene Ther, 2011 Mar 18; 18(8). PMID: 21412283    Free PMC article.
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.
Sergio A Quezada, Karl S Peggs, Tyler R Simpson, James P Allison.
Immunol Rev, 2011 Apr 15; 241(1). PMID: 21488893    Free PMC article.
Highly Cited. Review.
Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy.
Brandon Kwong, Haipeng Liu, Darrell J Irvine.
Biomaterials, 2011 Apr 26; 32(22). PMID: 21514665    Free PMC article.
Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production.
Michael A Curran, Myoungjoo Kim, +2 authors, James P Allison.
PLoS One, 2011 May 12; 6(4). PMID: 21559358    Free PMC article.
Highly Cited.
Cancer immunotherapy: Progress and challenges in the clinical setting.
Hassane M Zarour, Soldano Ferrone.
Eur J Immunol, 2011 May 28; 41(6). PMID: 21618503    Free PMC article.
Dichotomous effects of IFN-γ on dendritic cell function determine the extent of IL-12-driven antitumor T cell immunity.
Jamie L Harden, Tao Gu, +3 authors, Nejat K Egilmez.
J Immunol, 2011 Jun 03; 187(1). PMID: 21632715    Free PMC article.
Emerging antibody combinations in oncology.
Stephen J Demarest, Kandasamy Hariharan, Jianying Dong.
MAbs, 2011 Jun 24; 3(4). PMID: 21697653    Free PMC article.
PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells.
Katarzyna Karwacz, Christopher Bricogne, +4 authors, David Escors.
EMBO Mol Med, 2011 Jul 09; 3(10). PMID: 21739608    Free PMC article.
Novel immunotherapeutic agents and small molecule antagonists of signalling kinases for the treatment of metastatic melanoma.
Nagendra Natarajan, Sucheta Telang, Donald Miller, Jason Chesney.
Drugs, 2011 Jul 21; 71(10). PMID: 21770473
Chronic chemoimmunotherapy achieves cure of spontaneous murine mammary tumors via persistent blockade of posttherapy counter-regulation.
Rachael B Rowswell-Turner, Jamie L Harden, +3 authors, Nejat K Egilmez.
J Immunol, 2011 Sep 13; 187(8). PMID: 21908736    Free PMC article.
Evaluation of current cancer immunotherapy: hemato-oncology.
Christopher S Hourigan, Hyam I Levitsky.
Cancer J, 2011 Sep 29; 17(5). PMID: 21952281    Free PMC article.
Cancer immunotherapy comes of age.
Suzanne L Topalian, George J Weiner, Drew M Pardoll.
J Clin Oncol, 2011 Nov 02; 29(36). PMID: 22042955    Free PMC article.
Highly Cited. Review.
Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.
Xiang-Yang Wang, Daming Zuo, Devanand Sarkar, Paul B Fisher.
Expert Opin Pharmacother, 2011 Nov 15; 12(17). PMID: 22077831    Free PMC article.
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor.
Adam T Waickman, Angela Alme, +3 authors, Jonathan D Powell.
Cancer Immunol Immunother, 2011 Nov 26; 61(6). PMID: 22116345    Free PMC article.
Blockade of the B7-H1/PD-1 pathway for cancer immunotherapy.
Dallas B Flies, Britt J Sandler, Mario Sznol, Lieping Chen.
Yale J Biol Med, 2011 Dec 20; 84(4). PMID: 22180678    Free PMC article.
Profile of ipilimumab and its role in the treatment of metastatic melanoma.
Sapna P Patel, Scott E Woodman.
Drug Des Devel Ther, 2012 Jan 24; 5. PMID: 22267918    Free PMC article.
On the Mechanism of T cell receptor down-modulation and its physiological significance.
David Escors, Christopher Bricogne, +2 authors, Katarzyna Karwacz.
J Biosci Med, 2012 Feb 10; 1(1). PMID: 22318485    Free PMC article.
Soluble factors secreted by glioblastoma cell lines facilitate recruitment, survival, and expansion of regulatory T cells: implications for immunotherapy.
Courtney A Crane, Brian J Ahn, Seunggu J Han, Andrew T Parsa.
Neuro Oncol, 2012 Mar 13; 14(5). PMID: 22406925    Free PMC article.
Combining immunotherapy and targeted therapies in cancer treatment.
Matthew Vanneman, Glenn Dranoff.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437869    Free PMC article.
Highly Cited. Review.
Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma.
Michael A Postow, James Harding, Jedd D Wolchok.
Cancer J, 2012 Mar 29; 18(2). PMID: 22453017    Free PMC article.
Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Ping Yu, Jason C Steel, +5 authors, Thomas A Waldmann.
Proc Natl Acad Sci U S A, 2012 Apr 05; 109(16). PMID: 22474386    Free PMC article.
Repertoire enhancement with adoptively transferred female lymphocytes controls the growth of pre-implanted murine prostate cancer.
Robert R Jenq, Michael A Curran, +3 authors, Marcel R M van den Brink.
PLoS One, 2012 Apr 12; 7(4). PMID: 22493742    Free PMC article.
Immunotherapy of cancer in 2012.
John M Kirkwood, Lisa H Butterfield, +3 authors, Soldano Ferrone.
CA Cancer J Clin, 2012 May 12; 62(5). PMID: 22576456    Free PMC article.
Highly Cited. Review.
Strategies to use immune modulators in therapeutic vaccines against cancer.
Jay A Berzofsky, Masaki Terabe, Lauren V Wood.
Semin Oncol, 2012 May 19; 39(3). PMID: 22595057    Free PMC article.
Programmed death ligand 2 in cancer-induced immune suppression.
Esdy N Rozali, Stanleyson V Hato, +2 authors, W Joost Lesterhuis.
Clin Dev Immunol, 2012 May 23; 2012. PMID: 22611421    Free PMC article.
Highly Cited. Review.
The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses.
Russell K Pachynski, Brian A Zabel, +10 authors, Eugene C Butcher.
J Exp Med, 2012 Jul 04; 209(8). PMID: 22753924    Free PMC article.
Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients.
A J Robert McGray, Dannie Bernard, +8 authors, Jonathan L Bramson.
Oncoimmunology, 2012 Jul 04; 1(4). PMID: 22754760    Free PMC article.
MFG-E8 regulates the immunogenic potential of dendritic cells primed with necrotic cell-mediated inflammatory signals.
Muhammad Baghdadi, Shigeki Chiba, +2 authors, Masahisa Jinushi.
PLoS One, 2012 Jul 05; 7(6). PMID: 22761839    Free PMC article.
Towards curative cancer immunotherapy: overcoming posttherapy tumor escape.
Gang Zhou, Hyam Levitsky.
Clin Dev Immunol, 2012 Jul 11; 2012. PMID: 22778760    Free PMC article.
Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.
Sivan Sapoznik, Ohad Hammer, +4 authors, Gal Markel.
Clin Dev Immunol, 2012 Jul 11; 2012. PMID: 22778766    Free PMC article.
Induced and natural regulatory T cells in human cancer.
Theresa L Whiteside, Patrick Schuler, Bastian Schilling.
Expert Opin Biol Ther, 2012 Aug 02; 12(10). PMID: 22849383    Free PMC article.
PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines.
Weiyi Peng, Chengwen Liu, +8 authors, Patrick Hwu.
Cancer Res, 2012 Aug 24; 72(20). PMID: 22915761    Free PMC article.
Highly Cited.
Combination immunotherapy approaches.
C G Drake.
Ann Oncol, 2012 Aug 29; 23 Suppl 8. PMID: 22918927    Free PMC article.
Selective BRAF inhibition decreases tumor-resident lymphocyte frequencies in a mouse model of human melanoma.
Anna Hooijkaas, Jules Gadiot, +3 authors, Christian U Blank.
Oncoimmunology, 2012 Aug 31; 1(5). PMID: 22934253    Free PMC article.
The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy.
Telma Lança, Bruno Silva-Santos.
Oncoimmunology, 2012 Aug 31; 1(5). PMID: 22934263    Free PMC article.
Therese Liechtenstein, Ines Dufait, +2 authors, David Escors.
Immunol Endocr Metab Agents Med Chem, 2012 Sep 05; 12(3). PMID: 22945252    Free PMC article.
T-cell inhibitors: a bench-to-bedside review.
Shinjita Das, Kiyoshi Ariizumi, Ponciano D Cruz.
Dermatitis, 2012 Sep 27; 23(5). PMID: 23010825    Free PMC article.
Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal.
Yuning Lu, Helga Schneider, Christopher E Rudd.
Blood, 2012 Oct 11; 120(23). PMID: 23047820    Free PMC article.
Marek's disease virus infection induces widespread differential chromatin marks in inbred chicken lines.
Apratim Mitra, Juan Luo, +3 authors, Jiuzhou Song.
BMC Genomics, 2012 Oct 18; 13. PMID: 23072359    Free PMC article.
Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more.
Meghan E Turnis, Alan J Korman, Charles G Drake, Dario A A Vignali.
Oncoimmunology, 2012 Nov 22; 1(7). PMID: 23170269    Free PMC article.
Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.
Melissa M Berrien-Elliott, Stephanie R Jackson, +6 authors, Ryan M Teague.
Cancer Res, 2012 Nov 29; 73(2). PMID: 23188506    Free PMC article.
Combined targeted therapy and immunotherapy in the treatment of advanced melanoma.
James S Wilmott, Richard A Scolyer, Georgina V Long, Peter Hersey.
Oncoimmunology, 2012 Nov 29; 1(6). PMID: 23189245    Free PMC article.
Immunotherapies: the blockade of inhibitory signals.
Yan-Ling Wu, Jing Liang, +2 authors, Hiroshi Sugiyama.
Int J Biol Sci, 2012 Dec 01; 8(10). PMID: 23197939    Free PMC article.
Effector CD4 and CD8 T cells and their role in the tumor microenvironment.
Sine Hadrup, Marco Donia, Per Thor Straten.
Cancer Microenviron, 2012 Dec 18; 6(2). PMID: 23242673    Free PMC article.
Regulatory T cells in HIV infection: can immunotherapy regulate the regulator?
Mohammad-Ali Jenabian, Petronela Ancuta, Norbert Gilmore, Jean-Pierre Routy.
Clin Dev Immunol, 2012 Dec 20; 2012. PMID: 23251223    Free PMC article.
Materials based tumor immunotherapy vaccines.
Weiwei Aileen Li, David J Mooney.
Curr Opin Immunol, 2013 Jan 23; 25(2). PMID: 23337254    Free PMC article.
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Joseph F Grosso, Maria N Jure-Kunkel.
Cancer Immun, 2013 Feb 08; 13. PMID: 23390376    Free PMC article.
Highly Cited. Review.
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
Mario Sznol, Lieping Chen.
Clin Cancer Res, 2013 Mar 06; 19(5). PMID: 23460533    Free PMC article.
Highly Cited.
T-cell modulatory properties of CD5 and its role in antitumor immune responses.
Mouna Tabbekh, M'barka Mokrani-Hammani, Georges Bismuth, Fathia Mami-Chouaib.
Oncoimmunology, 2013 Mar 14; 2(1). PMID: 23483035    Free PMC article.
Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy.
Isabela Pedroza-Pacheco, Alejandro Madrigal, Aurore Saudemont.
Cell Mol Immunol, 2013 Mar 26; 10(3). PMID: 23524654    Free PMC article.
PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal.
Therese Liechtenstein, Ines Dufait, +4 authors, David Escors.
J Clin Cell Immunol, 2013 Mar 26; S12. PMID: 23525238    Free PMC article.
PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis.
Bernd H Zinselmeyer, Sara Heydari, +7 authors, Dorian B McGavern.
J Exp Med, 2013 Mar 27; 210(4). PMID: 23530125    Free PMC article.
Highly Cited.
Modulation of tumor immunity by soluble and membrane-bound molecules at the immunological synapse.
Pablo A González, Leandro J Carreño, +3 authors, Alexis M Kalergis.
Clin Dev Immunol, 2013 Mar 28; 2013. PMID: 23533456    Free PMC article.
Restoring immune function of tumor-specific CD4+ T cells during recurrence of melanoma.
Stephen R Goding, Kyle A Wilson, +7 authors, Paul Andrew Antony.
J Immunol, 2013 Mar 29; 190(9). PMID: 23536636    Free PMC article.
Highly Cited.
Lack of PD-L1 expression by iNKT cells improves the course of influenza A infection.
Hadi Maazi, Abinav K Singh, +7 authors, Omid Akbari.
PLoS One, 2013 Apr 05; 8(3). PMID: 23555047    Free PMC article.
The immunologic basis for severe neonatal herpes disease and potential strategies for therapeutic intervention.
Soren Gantt, William J Muller.
Clin Dev Immunol, 2013 Apr 23; 2013. PMID: 23606868    Free PMC article.
Strategies to reverse melanoma-induced T-cell dysfunction.
Julien Fourcade, Hassane M Zarour.
Clin Dermatol, 2013 Apr 24; 31(3). PMID: 23608444    Free PMC article.
The tumor microenvironment: a pitch for multiple players.
Giovanna Schiavoni, Lucia Gabriele, Fabrizio Mattei.
Front Oncol, 2013 Apr 26; 3. PMID: 23616948    Free PMC article.
At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.
Andrew M Intlekofer, Craig B Thompson.
J Leukoc Biol, 2013 Apr 30; 94(1). PMID: 23625198    Free PMC article.
Highly Cited. Review.
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Jaikumar Duraiswamy, Karen M Kaluza, Gordon J Freeman, George Coukos.
Cancer Res, 2013 May 02; 73(12). PMID: 23633484    Free PMC article.
Highly Cited.
Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects.
John Stagg, Bertrand Allard.
Ther Adv Med Oncol, 2013 May 02; 5(3). PMID: 23634195    Free PMC article.
The impact of the myeloid response to radiation therapy.
Michael J Gough, Kristina Young, Marka Crittenden.
Clin Dev Immunol, 2013 May 09; 2013. PMID: 23653658    Free PMC article.
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
Margaret K Callahan, Jedd D Wolchok.
J Leukoc Biol, 2013 May 15; 94(1). PMID: 23667165    Free PMC article.
Highly Cited. Review.
Optimal management of metastatic melanoma: current strategies and future directions.
Marta Batus, Salman Waheed, +3 authors, Howard L Kaufman.
Am J Clin Dermatol, 2013 May 17; 14(3). PMID: 23677693    Free PMC article.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Targeting immunosuppression for cancer therapy.
Cristina Ghirelli, Thorsten Hagemann.
J Clin Invest, 2013 Jun 04; 123(6). PMID: 23728169    Free PMC article.
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
Rikke B Holmgaard, Dmitriy Zamarin, +2 authors, James P Allison.
J Exp Med, 2013 Jun 12; 210(7). PMID: 23752227    Free PMC article.
Highly Cited.
Properties of immature myeloid progenitors with nitric-oxide-dependent immunosuppressive activity isolated from bone marrow of tumor-free mice.
Parvin Forghani, Wayne Harris, +3 authors, Edmund K Waller.
PLoS One, 2013 Jul 12; 8(7). PMID: 23843936    Free PMC article.
New insights into the role of the immune microenvironment in breast carcinoma.
Luis de la Cruz-Merino, Antonio Barco-Sánchez, +12 authors, José Ibáñez Martínez.
Clin Dev Immunol, 2013 Jul 19; 2013. PMID: 23861693    Free PMC article.
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
Christopher J Nirschl, Charles G Drake.
Clin Cancer Res, 2013 Jul 23; 19(18). PMID: 23868869    Free PMC article.
Highly Cited. Review.
Therapeutic cancer vaccines: past, present, and future.
Chunqing Guo, Masoud H Manjili, +3 authors, Xiang-Yang Wang.
Adv Cancer Res, 2013 Jul 23; 119. PMID: 23870514    Free PMC article.
Highly Cited. Review.
Natural and induced T regulatory cells in cancer.
Dennis O Adeegbe, Hiroyoshi Nishikawa.
Front Immunol, 2013 Jul 23; 4. PMID: 23874336    Free PMC article.
Highly Cited.
Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies.
Yannick Bulliard, Rose Jolicoeur, +6 authors, Jennifer L Brogdon.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897982    Free PMC article.
Highly Cited.
Immunomodulation via Chemotherapy and Targeted Therapy: A New Paradigm in Breast Cancer Therapy?
John Stagg, Fabrice Andre, Sherene Loi.
Breast Care (Basel), 2013 Aug 02; 7(4). PMID: 23904828    Free PMC article.
Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Jaikumar Duraiswamy, Gordon J Freeman, George Coukos.
Cancer Res, 2013 Aug 27; 73(23). PMID: 23975756    Free PMC article.
Highly Cited.
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
Stefani Spranger, Robbert M Spaapen, +4 authors, Thomas F Gajewski.
Sci Transl Med, 2013 Aug 30; 5(200). PMID: 23986400    Free PMC article.
Highly Cited.
Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
Nune Markosyan, Edward P Chen, +3 authors, Emer M Smyth.
Breast Cancer Res, 2013 Sep 06; 15(5). PMID: 24004819    Free PMC article.
Innate and adaptive immune cells in the tumor microenvironment.
Thomas F Gajewski, Hans Schreiber, Yang-Xin Fu.
Nat Immunol, 2013 Sep 21; 14(10). PMID: 24048123    Free PMC article.
Highly Cited. Review.
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
Esra A Akbay, Shohei Koyama, +24 authors, Kwok-Kin Wong.
Cancer Discov, 2013 Oct 01; 3(12). PMID: 24078774    Free PMC article.
Highly Cited.
Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy.
Christel Devaud, Liza B John, +2 authors, Michael H Kershaw.
Oncoimmunology, 2013 Oct 02; 2(8). PMID: 24083084    Free PMC article.
Highly Cited. Review.
Transient regulatory T cell ablation deters oncogene-driven breast cancer and enhances radiotherapy.
Paula D Bos, George Plitas, +2 authors, Alexander Y Rudensky.
J Exp Med, 2013 Oct 16; 210(11). PMID: 24127486    Free PMC article.
Highly Cited.
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Brendan D Curti, Magdalena Kovacsovics-Bankowski, +20 authors, Andrew D Weinberg.
Cancer Res, 2013 Nov 02; 73(24). PMID: 24177180    Free PMC article.
Highly Cited.
Immune modulation by chemotherapy or immunotherapy to enhance cancer vaccines.
Genevieve M Weir, Robert S Liwski, Marc Mansour.
Cancers (Basel), 2011 Jan 01; 3(3). PMID: 24212948    Free PMC article.
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application.
Taku Okazaki, Shunsuke Chikuma, +2 authors, Tasuku Honjo.
Nat Immunol, 2013 Nov 19; 14(12). PMID: 24240160
Highly Cited. Review.
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.
Charles G Drake, Evan J Lipson, Julie R Brahmer.
Nat Rev Clin Oncol, 2013 Nov 20; 11(1). PMID: 24247168    Free PMC article.
Highly Cited. Review.
Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.
Liufu Deng, Hua Liang, +4 authors, Yang-Xin Fu.
J Clin Invest, 2014 Jan 03; 124(2). PMID: 24382348    Free PMC article.
Highly Cited.
PD-1 as a potential target in cancer therapy.
David F McDermott, Michael B Atkins.
Cancer Med, 2014 Jan 10; 2(5). PMID: 24403232    Free PMC article.
Highly Cited. Review.
Replenish the source within: Rescuing tumor-infiltrating lymphocytes by double checkpoint blockade.
Jaikumar Duraiswamy, Gordon Freeman, George Coukos.
Oncoimmunology, 2014 Jan 10; 2(10). PMID: 24404420    Free PMC article.
Tumor immunology: multidisciplinary science driving basic and clinical advances.
Bridget P Keenan, Elizabeth M Jaffee, Todd D Armstrong.
Cancer Immunol Res, 2014 Jan 11; 1(1). PMID: 24409447    Free PMC article.
Transnuclear TRP1-specific CD8 T cells with high or low affinity TCRs show equivalent antitumor activity.
Stephanie K Dougan, Michael Dougan, +6 authors, Hidde L Ploegh.
Cancer Immunol Res, 2014 Jan 25; 1(2). PMID: 24459675    Free PMC article.
Inclusion of CD80 in HSV targets the recombinant virus to PD-L1 on DCs and allows productive infection and robust immune responses.
Kevin R Mott, Sariah J Allen, +7 authors, Homayon Ghiasi.
PLoS One, 2014 Jan 30; 9(1). PMID: 24475315    Free PMC article.
In vivo discovery of immunotherapy targets in the tumour microenvironment.
Penghui Zhou, Donald R Shaffer, +17 authors, Kai W Wucherpfennig.
Nature, 2014 Jan 31; 506(7486). PMID: 24476824    Free PMC article.
Highly Cited.
Immunotherapy for solid tumors--a review for surgeons.
Abdul Saied, Venu G Pillarisetty, Steven C Katz.
J Surg Res, 2014 Feb 04; 187(2). PMID: 24485876    Free PMC article.
Mathematical models of immune-induced cancer dormancy and the emergence of immune evasion.
Kathleen P Wilkie, Philip Hahnfeldt.
Interface Focus, 2014 Feb 11; 3(4). PMID: 24511375    Free PMC article.
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.
Dmitriy Zamarin, Rikke B Holmgaard, +6 authors, James P Allison.
Sci Transl Med, 2014 Mar 07; 6(226). PMID: 24598590    Free PMC article.
Highly Cited.
Immunologic and clinical effects of targeting PD-1 in lung cancer.
R D Harvey.
Clin Pharmacol Ther, 2014 Apr 03; 96(2). PMID: 24690569    Free PMC article.
Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors.
Derek A Wainwright, Alan L Chang, +9 authors, Maciej S Lesniak.
Clin Cancer Res, 2014 Apr 03; 20(20). PMID: 24691018    Free PMC article.
Highly Cited.
VISTA Regulates the Development of Protective Antitumor Immunity.
Isabelle Le Mercier, Wenna Chen, +5 authors, Li Wang.
Cancer Res, 2014 Apr 03; 74(7). PMID: 24691994    Free PMC article.
Highly Cited.
Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.
Linda C Sandin, Fredrik Eriksson, +3 authors, Sara M Mangsbo.
Oncoimmunology, 2014 Apr 05; 3(1). PMID: 24701377    Free PMC article.
Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.
Lavakumar Karyampudi, Purushottam Lamichhane, +5 authors, Keith L Knutson.
Cancer Res, 2014 Apr 15; 74(11). PMID: 24728077    Free PMC article.
Pathways and therapeutic targets in melanoma.
Emma Shtivelman, Michael Q A Davies, +5 authors, David E Fisher.
Oncotarget, 2014 Apr 20; 5(7). PMID: 24743024    Free PMC article.
Highly Cited. Review.
Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
William L Redmond, Stefanie N Linch, Melissa J Kasiewicz.
Cancer Immunol Res, 2014 Apr 30; 2(2). PMID: 24778278    Free PMC article.
Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.
Francesca Avogadri, Roberta Zappasodi, +8 authors, Taha Merghoub.
Cancer Immunol Res, 2014 May 06; 2(5). PMID: 24795357    Free PMC article.
Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors.
Juan Fu, Ian-James Malm, +3 authors, Young J Kim.
Cancer Res, 2014 May 09; 74(15). PMID: 24812273    Free PMC article.
Oncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus h-1.
Markus Moehler, Katrin Goepfert, +4 authors, Jean Rommelaere.
Front Oncol, 2014 May 14; 4. PMID: 24822170    Free PMC article.
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy.
Mikayel Mkrtichyan, Namju Chong, +4 authors, Samir N Khleif.
J Immunother Cancer, 2013 Jan 01; 1. PMID: 24829751    Free PMC article.
Immunotherapy in the treatment of non-small cell lung cancer.
Raghav Sundar, Richie Soong, +2 authors, Ross A Soo.
Lung Cancer, 2014 Jun 02; 85(2). PMID: 24880938    Free PMC article.
Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer.
Raju R Raval, Andrew B Sharabi, +2 authors, Padmanee Sharma.
J Immunother Cancer, 2014 Jun 03; 2. PMID: 24883190    Free PMC article.
What have we learned from cancer immunotherapy in the last 3 years?
Paolo A Ascierto, Francesco M Marincola.
J Transl Med, 2014 Jun 03; 12. PMID: 24886164    Free PMC article.
Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1.
Yi-Chi M Kong, Jeffrey C Flynn.
Front Immunol, 2014 Jun 07; 5. PMID: 24904570    Free PMC article.
Induced regulatory T cells in inhibitory microenvironments created by cancer.
Theresa L Whiteside.
Expert Opin Biol Ther, 2014 Jun 18; 14(10). PMID: 24934899    Free PMC article.
Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review).
Sadek Malas, Micaela Harrasser, Katie E Lacy, Sophia N Karagiannis.
Oncol Rep, 2014 Jun 28; 32(3). PMID: 24969320    Free PMC article.
Therapeutic vaccines for cancer: an overview of clinical trials.
Ignacio Melero, Gustav Gaudernack, +8 authors, Håkan Mellstedt.
Nat Rev Clin Oncol, 2014 Jul 09; 11(9). PMID: 25001465
Highly Cited. Review.
Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.
Miguel F Sanmamed, Lieping Chen.
Cancer J, 2014 Aug 08; 20(4). PMID: 25098285    Free PMC article.
Targeting immune co-stimulatory effects of PD-L1 and PD-L2 might represent an effective therapeutic strategy in stroke.
Sheetal Bodhankar, Yingxin Chen, +3 authors, Halina Offner.
Front Cell Neurosci, 2014 Aug 27; 8. PMID: 25157219    Free PMC article.
Combining radiation and immunotherapy: a new systemic therapy for solid tumors?
Chad Tang, Xiaohong Wang, +14 authors, James W Welsh.
Cancer Immunol Res, 2014 Sep 05; 2(9). PMID: 25187273    Free PMC article.
Highly Cited. Review.
Immune checkpoint inhibitors in clinical trials.
Elad Sharon, Howard Streicher, Priscila Goncalves, Helen X Chen.
Chin J Cancer, 2014 Sep 06; 33(9). PMID: 25189716    Free PMC article.
Cancer immunotherapy in clinical practice -- the past, present, and future.
Gaurav Goel, Weijing Sun.
Chin J Cancer, 2014 Sep 06; 33(9). PMID: 25189717    Free PMC article.
Immunotherapy advances for glioblastoma.
David A Reardon, Gordon Freeman, +7 authors, Glenn Dranoff.
Neuro Oncol, 2014 Sep 06; 16(11). PMID: 25190673    Free PMC article.
Highly Cited. Review.
Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.
Manisha Singh, Hiep Khong, +6 authors, Willem W Overwijk.
J Immunol, 2014 Sep 26; 193(9). PMID: 25252955    Free PMC article.
Kupfer-type immunological synapses in vivo: Raison D'être of SMAC.
Izaskun Mitxitorena, Elena Saavedra, Carlos Barcia.
Immunol Cell Biol, 2014 Oct 01; 93(1). PMID: 25267483
The programmed death-1 immune-suppressive pathway: barrier to antitumor immunity.
Suzanne Ostrand-Rosenberg, Lucas A Horn, Samuel T Haile.
J Immunol, 2014 Oct 05; 193(8). PMID: 25281753    Free PMC article.
Highly Cited. Review.
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Stephanie R Jackson, Jinyun Yuan, Ryan M Teague.
Immunotherapy, 2014 Oct 08; 6(7). PMID: 25290416    Free PMC article.
A nervous tumor microenvironment: the impact of adrenergic stress on cancer cells, immunosuppression, and immunotherapeutic response.
Jason W-L Eng, Kathleen M Kokolus, +3 authors, Elizabeth A Repasky.
Cancer Immunol Immunother, 2014 Oct 14; 63(11). PMID: 25307152    Free PMC article.
The Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.
Vladimir Mouraviev, Neil Mariados, +5 authors, Christopher M Pieczonka.
Rev Urol, 2014 Oct 23; 16(3). PMID: 25337042    Free PMC article.
[Advances of PD-1/PD-L1 signaling pathway in immune escape and treatment for 
non-small cell lung cancer].
Cheng Lin, Xiong Chen, +2 authors, Xuenong Ou-Yang.
Zhongguo Fei Ai Za Zhi, 2014 Oct 25; 17(10). PMID: 25342040    Free PMC article.
Neuropilin-1 expression is induced on tolerant self-reactive CD8+ T cells but is dispensable for the tolerant phenotype.
Stephanie R Jackson, Melissa Berrien-Elliott, +2 authors, Ryan M Teague.
PLoS One, 2014 Oct 25; 9(10). PMID: 25343644    Free PMC article.
The immunological synapse.
Michael L Dustin.
Cancer Immunol Res, 2014 Nov 05; 2(11). PMID: 25367977    Free PMC article.
Highly Cited. Review.
Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.
Michael R Olin, G Elizabeth Pluhar, +3 authors, Christopher L Moertel.
Crit Rev Immunol, 2014 Nov 19; 34(5). PMID: 25404047    Free PMC article.
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Matthew M Gubin, Xiuli Zhang, +24 authors, Robert D Schreiber.
Nature, 2014 Nov 28; 515(7528). PMID: 25428507    Free PMC article.
Highly Cited.
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Kim C Ohaegbulam, Amer Assal, +2 authors, Xingxing Zang.
Trends Mol Med, 2014 Dec 03; 21(1). PMID: 25440090    Free PMC article.
Highly Cited. Review.
Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.
Abhishek Tripathi, Charles G Drake, Lauren C Harshman.
BioDrugs, 2014 Dec 03; 28(6). PMID: 25445176    Free PMC article.
Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.
Miranda L Broz, Mikhail Binnewies, +12 authors, Matthew F Krummel.
Cancer Cell, 2014 Dec 03; 26(5). PMID: 25446897    Free PMC article.
Highly Cited.
Chemokines in cancer.
Melvyn T Chow, Andrew D Luster.
Cancer Immunol Res, 2014 Dec 07; 2(12). PMID: 25480554    Free PMC article.
Highly Cited. Review.
CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany.
Mustafa Diken, Sebastian Boegel, +6 authors, Sebastian Kreiter.
Hum Vaccin Immunother, 2014 Dec 09; 10(10). PMID: 25483671    Free PMC article.
The delicate balance of melanoma immunotherapy.
David E Gyorki, Margaret Callahan, Jedd D Wolchok, Charlotte E Ariyan.
Clin Transl Immunology, 2013 Aug 01; 2(8). PMID: 25505953    Free PMC article.
Checkpoint blockade immunotherapy relies on T-bet but not Eomes to induce effector function in tumor-infiltrating CD8+ T cells.
Melissa M Berrien-Elliott, Jinyun Yuan, +4 authors, Ryan M Teague.
Cancer Immunol Res, 2014 Dec 18; 3(2). PMID: 25516478    Free PMC article.
Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma.
Geoffrey T Gibney, Ragini R Kudchadkar, +13 authors, Jeffrey S Weber.
Clin Cancer Res, 2014 Dec 20; 21(4). PMID: 25524312    Free PMC article.
Highly Cited.
Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo.
Rituparna Das, Rakesh Verma, +8 authors, Kavita M Dhodapkar.
J Immunol, 2014 Dec 30; 194(3). PMID: 25539810    Free PMC article.
Highly Cited.
PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation.
Mei Ji, Yan Liu, +6 authors, Chang-Ping Wu.
J Transl Med, 2015 Jan 17; 13. PMID: 25592115    Free PMC article.
CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.
Christopher L Moertel, Junzhe Xia, +9 authors, Michael R Olin.
J Immunother Cancer, 2015 Jan 20; 2(1). PMID: 25598973    Free PMC article.
CD4 T Cells Mediate Both Positive and Negative Regulation of the Immune Response to HIV Infection: Complex Role of T Follicular Helper Cells and Regulatory T Cells in Pathogenesis.
Chansavath Phetsouphanh, Yin Xu, John Zaunders.
Front Immunol, 2015 Jan 23; 5. PMID: 25610441    Free PMC article.
Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma.
Weiqing Jing, Jill A Gershan, +4 authors, Bryon D Johnson.
J Immunother Cancer, 2015 Jan 24; 3(1). PMID: 25614821    Free PMC article.
CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic.
Margaret K Callahan, Michael A Postow, Jedd D Wolchok.
Front Oncol, 2015 Feb 03; 4. PMID: 25642417    Free PMC article.
Highly Cited. Review.
Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.
Rafael Winograd, Katelyn T Byrne, +8 authors, Robert H Vonderheide.
Cancer Immunol Res, 2015 Feb 14; 3(4). PMID: 25678581    Free PMC article.
Highly Cited.
An update on current management of advanced renal cell cancer, biomarkers, and future directions.
Wanqing Iris Zhi, Jenny J Kim.
Ann Cancer Res, 2015 Feb 28; 1(2). PMID: 25722991    Free PMC article.
Biomarkers for glioma immunotherapy: the next generation.
Jennifer S Sims, Timothy H Ung, +2 authors, Jeffrey N Bruce.
J Neurooncol, 2015 Mar 01; 123(3). PMID: 25724916    Free PMC article.
Blockade of PD-1/PD-L1 promotes adoptive T-cell immunotherapy in a tolerogenic environment.
Stephen J P Blake, Alan L H Ching, +4 authors, Raymond J Steptoe.
PLoS One, 2015 Mar 06; 10(3). PMID: 25741704    Free PMC article.
The role of checkpoints in the treatment of GBM.
Jennifer E Kim, Michael Lim.
J Neurooncol, 2015 Mar 10; 123(3). PMID: 25749875    Free PMC article.
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer.
Christina Twyman-Saint Victor, Andrew J Rech, +22 authors, Andy J Minn.
Nature, 2015 Mar 11; 520(7547). PMID: 25754329    Free PMC article.
Highly Cited.
Nivolumab in NSCLC: latest evidence and clinical potential.
Raghav Sundar, Byoung-Chul Cho, Julie R Brahmer, Ross A Soo.
Ther Adv Med Oncol, 2015 Mar 11; 7(2). PMID: 25755681    Free PMC article.
Highly Cited. Review.
Nivolumab in melanoma: latest evidence and clinical potential.
Douglas B Johnson, Chengwei Peng, Jeffrey A Sosman.
Ther Adv Med Oncol, 2015 Mar 11; 7(2). PMID: 25755682    Free PMC article.
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal.
Stefanie N Linch, Michael J McNamara, William L Redmond.
Front Oncol, 2015 Mar 13; 5. PMID: 25763356    Free PMC article.
Highly Cited. Review.
β-Cell-targeted blockage of PD1 and CTLA4 pathways prevents development of autoimmune diabetes and acute allogeneic islets rejection.
M M El Khatib, T Sakuma, +5 authors, Y Ikeda.
Gene Ther, 2015 Mar 20; 22(5). PMID: 25786871    Free PMC article.
Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells.
Suzanne Ostrand-Rosenberg, Lucas A Horn, Juan A Alvarez.
Cancer Immunol Immunother, 2015 Mar 21; 64(10). PMID: 25792524    Free PMC article.
The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date.
Katy K Tsai, Adil I Daud.
Drugs, 2015 Mar 25; 75(6). PMID: 25802230
γδ T cell therapy for the treatment of non-small cell lung cancer.
Kazuhiro Kakimi, Hirokazu Matsushita, Tomohiro Murakawa, Jun Nakajima.
Transl Lung Cancer Res, 2015 Mar 26; 3(1). PMID: 25806278    Free PMC article.
Stress, metabolism and cancer: integrated pathways contributing to immune suppression.
Elizabeth A Repasky, Jason Eng, Bonnie L Hylander.
Cancer J, 2015 Mar 31; 21(2). PMID: 25815849    Free PMC article.
Peripheral myeloid-derived suppressor and T regulatory PD-1 positive cells predict response to neoadjuvant short-course radiotherapy in rectal cancer patients.
Maria Napolitano, Crescenzo D'Alterio, +11 authors, Stefania Scala.
Oncotarget, 2015 Apr 01; 6(10). PMID: 25823653    Free PMC article.
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Kathleen M Mahoney, Gordon J Freeman, David F McDermott.
Clin Ther, 2015 Apr 01; 37(4). PMID: 25823918    Free PMC article.
Highly Cited. Review.
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers.
B Homet Moreno, A Ribas.
Br J Cancer, 2015 Apr 10; 112(9). PMID: 25856776    Free PMC article.
Highly Cited. Review.
Immunotherapy in Cancer: A Combat between Tumors and the Immune System; You Win Some, You Lose Some.
Florencia Paula Madorsky Rowdo, Antonela Baron, Mariela Urrutia, José Mordoh.
Front Immunol, 2015 Apr 11; 6. PMID: 25859247    Free PMC article.
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.
Padmanee Sharma, James P Allison.
Cell, 2015 Apr 11; 161(2). PMID: 25860605    Free PMC article.
Highly Cited. Review.
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.
Alexander Filatenkov, Jeanette Baker, +11 authors, Samuel Strober.
Clin Cancer Res, 2015 Apr 15; 21(16). PMID: 25869387    Free PMC article.
Highly Cited.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, +18 authors, F Stephen Hodi.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891304    Free PMC article.
Highly Cited.
Tumor infiltrating lymphocytes in ovarian cancer.
Phillip P Santoiemma, Daniel J Powell.
Cancer Biol Ther, 2015 Apr 22; 16(6). PMID: 25894333    Free PMC article.
Highly Cited. Review.
B7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor Immunity.
Ming-Ru Wu, Tong Zhang, +3 authors, Charles L Sentman.
J Immunol, 2015 Apr 26; 194(11). PMID: 25911747    Free PMC article.
Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model.
Russell K Pachynski, Alexander Scholz, +2 authors, Brian A Zabel.
J Vis Exp, 2015 May 06; (98). PMID: 25938949    Free PMC article.
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses.
Jun Liu, Ying Yuan, +8 authors, Li Wang.
Proc Natl Acad Sci U S A, 2015 May 13; 112(21). PMID: 25964334    Free PMC article.
Highly Cited.
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma.
Danielle M Lussier, John L Johnson, Pooja Hingorani, Joseph N Blattman.
J Immunother Cancer, 2015 May 21; 3. PMID: 25992292    Free PMC article.
Highly Cited.
Inhibitory receptors as targets for cancer immunotherapy.
Meghan E Turnis, Lawrence P Andrews, Dario A A Vignali.
Eur J Immunol, 2015 May 29; 45(7). PMID: 26018646    Free PMC article.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
Programmed death-1 checkpoint blockade in acute myeloid leukemia.
Alison Sehgal, Theresa L Whiteside, Michael Boyiadzis.
Expert Opin Biol Ther, 2015 Jun 04; 15(8). PMID: 26036819    Free PMC article.
Dendritic cell immunotherapy for brain tumors.
Joseph P Antonios, Richard G Everson, Linda M Liau.
J Neurooncol, 2015 Jun 04; 123(3). PMID: 26037466
Evolving Concepts: Immunity in Oncology from Targets to Treatments.
Hina Khan, Rasim Gucalp, Iuliana Shapira.
J Oncol, 2015 Jun 11; 2015. PMID: 26060497    Free PMC article.
Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Cheng Sun, Hao-yu Sun, +2 authors, Zhi-gang Tian.
Acta Pharmacol Sin, 2015 Jun 16; 36(10). PMID: 26073325    Free PMC article.
Regulatory B cells preferentially accumulate in tumor-draining lymph nodes and promote tumor growth.
Sheila N Ganti, Tina C Albershardt, Brian M Iritani, Alanna Ruddell.
Sci Rep, 2015 Jul 21; 5. PMID: 26193241    Free PMC article.
Evolving synergistic combinations of targeted immunotherapies to combat cancer.
Ignacio Melero, David M Berman, +3 authors, John Haanen.
Nat Rev Cancer, 2015 Jul 25; 15(8). PMID: 26205340
Highly Cited. Review.
The past, present and future of immunotherapy against tumor.
Tao Jiang, Caicun Zhou.
Transl Lung Cancer Res, 2015 Jul 25; 4(3). PMID: 26207213    Free PMC article.
IL-15 Superagonist-Mediated Immunotoxicity: Role of NK Cells and IFN-γ.
Yin Guo, Liming Luan, +4 authors, Edward R Sherwood.
J Immunol, 2015 Jul 29; 195(5). PMID: 26216888    Free PMC article.
Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy.
Maria Libera Ascierto, Ignacio Melero, Paolo Antonio Ascierto.
Front Oncol, 2015 Jul 29; 5. PMID: 26217587    Free PMC article.
Immunosuppressive Mechanisms of Malignant Gliomas: Parallels at Non-CNS Sites.
Powell Perng, Michael Lim.
Front Oncol, 2015 Jul 29; 5. PMID: 26217588    Free PMC article.
HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade.
David M Woods, Andressa L Sodré, +3 authors, Jeffrey Weber.
Cancer Immunol Res, 2015 Aug 25; 3(12). PMID: 26297712    Free PMC article.
Highly Cited.
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model.
Ruea-Yea Huang, Cheryl Eppolito, +3 authors, Kunle Odunsi.
Oncotarget, 2015 Sep 01; 6(29). PMID: 26318293    Free PMC article.
Highly Cited.
An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
A E Rice, Y E Latchman, +3 authors, F R Jones.
Cancer Gene Ther, 2015 Sep 05; 22(9). PMID: 26337747
Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy.
Giorgio Parmiani, Cristina Maccalli, Michele Maio.
Vaccines (Basel), 2015 Sep 08; 3(2). PMID: 26343195    Free PMC article.
Unique potential of 4-1BB agonist antibody to promote durable regression of HPV+ tumors when combined with an E6/E7 peptide vaccine.
Todd Bartkowiak, Shailbala Singh, +6 authors, Michael A Curran.
Proc Natl Acad Sci U S A, 2015 Sep 10; 112(38). PMID: 26351680    Free PMC article.
PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
Lina Quan, Xue Chen, +4 authors, Yue Liu.
PLoS One, 2015 Sep 12; 10(9). PMID: 26361042    Free PMC article.
Clinical significance of tumor-infiltrating immune cells focusing on BTLA and Cbl-b in patients with gallbladder cancer.
Seiji Oguro, Yoshinori Ino, +7 authors, Nobuyoshi Hiraoka.
Cancer Sci, 2015 Sep 24; 106(12). PMID: 26395180    Free PMC article.
Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression.
Wendy Wj Unger, Christian T Mayer, +9 authors, Yvette van Kooyk.
Oncoimmunology, 2015 Sep 26; 4(8). PMID: 26405564    Free PMC article.
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models.
A Covre, S Coral, +8 authors, M Maio.
Oncoimmunology, 2015 Sep 26; 4(8). PMID: 26405573    Free PMC article.
CD73: A potential biomarker for anti-PD-1 therapy.
Paul A Beavis, Clare Y Slaney, +5 authors, Phillip K Darcy.
Oncoimmunology, 2015 Oct 10; 4(11). PMID: 26451321    Free PMC article.
Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors.
Jennifer Kleponis, Richard Skelton, Lei Zheng.
Cancer Biol Med, 2015 Oct 22; 12(3). PMID: 26487965    Free PMC article.
Predictive factors for immunotherapy in melanoma.
Cristina Teixidó, Maria González-Cao, Niki Karachaliou, Rafael Rosell.
Ann Transl Med, 2015 Oct 22; 3(15). PMID: 26488004    Free PMC article.
Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination.
Christopher M Jackson, Christina M Kochel, +17 authors, Charles G Drake.
Clin Cancer Res, 2015 Oct 23; 22(5). PMID: 26490306    Free PMC article.
Immunotherapy for neuro-oncology: the critical rationale for combinatorial therapy.
David A Reardon, Mark R Gilbert, Wolfgang Wick, Linda Liau.
Neuro Oncol, 2015 Oct 31; 17 Suppl 7. PMID: 26516225    Free PMC article.
Nivolumab plus ipilimumab in the treatment of advanced melanoma.
Katy K Tsai, Adil I Daud.
J Hematol Oncol, 2015 Nov 01; 8. PMID: 26518223    Free PMC article.
Cancer immunotherapy: Strategies for personalization and combinatorial approaches.
Vishwanath Sathyanarayanan, Sattva S Neelapu.
Mol Oncol, 2015 Nov 10; 9(10). PMID: 26548534    Free PMC article.
CTLA-4 and PD-1 Pathways: Similarities, Differences, and Implications of Their Inhibition.
Elizabeth I Buchbinder, Anupam Desai.
Am J Clin Oncol, 2015 Nov 13; 39(1). PMID: 26558876    Free PMC article.
Highly Cited. Review.
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy.
Vinod Vijay Subhash, Mei Shi Yeo, Woei Loon Tan, Wei Peng Yong.
J Immunol Res, 2015 Nov 19; 2015. PMID: 26579545    Free PMC article.
Harnessing the Power of Onco-Immunotherapy with Checkpoint Inhibitors.
Karishma R Rajani, Richard G Vile.
Viruses, 2015 Nov 19; 7(11). PMID: 26580645    Free PMC article.
[Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer].
Zhiyu Huang, Hui Li, Yun Fan.
Zhongguo Fei Ai Za Zhi, 2015 Nov 20; 18(11). PMID: 26582228    Free PMC article.
Engineering opportunities in cancer immunotherapy.
Laura Jeanbart, Melody A Swartz.
Proc Natl Acad Sci U S A, 2015 Nov 26; 112(47). PMID: 26598681    Free PMC article.
Combination cancer immunotherapies tailored to the tumour microenvironment.
Mark J Smyth, Shin Foong Ngiow, Antoni Ribas, Michele W L Teng.
Nat Rev Clin Oncol, 2015 Nov 26; 13(3). PMID: 26598942
Highly Cited. Review.
MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints.
Jun Wei, Edjah K Nduom, +13 authors, Amy B Heimberger.
Neuro Oncol, 2015 Dec 15; 18(5). PMID: 26658052    Free PMC article.
Highly Cited.
Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication.
Omar A Ali, Sarah A Lewin, Glenn Dranoff, David J Mooney.
Cancer Immunol Res, 2015 Dec 17; 4(2). PMID: 26669718    Free PMC article.
Large molecular systems landscape uncovers T cell trapping in human skin cancer.
Reyk Hillert, Anne Gieseler, +5 authors, Walter Schubert.
Sci Rep, 2016 Jan 14; 6. PMID: 26757895    Free PMC article.
Expression of programmed cell death-ligand 1 and its correlation with clinical outcomes in gliomas.
Jing Zeng, Xin-Ke Zhang, +3 authors, Su-Xia Lin.
Oncotarget, 2016 Jan 16; 7(8). PMID: 26771840    Free PMC article.
Updates in Therapy for Advanced Melanoma.
Bhavana P Singh, April K S Salama.
Cancers (Basel), 2016 Jan 20; 8(1). PMID: 26784231    Free PMC article.
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18.
Silvia Carvalho, Francesca Levi-Schaffer, Michael Sela, Yosef Yarden.
Br J Pharmacol, 2016 Feb 03; 173(9). PMID: 26833433    Free PMC article.
Advances in immunotherapy for melanoma.
Jason M Redman, Geoffrey T Gibney, Michael B Atkins.
BMC Med, 2016 Feb 07; 14. PMID: 26850630    Free PMC article.
Highly Cited. Review.
Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
Joseph M Ryan, Jeffrey S Wasser, Adam J Adler, Anthony T Vella.
Expert Opin Biol Ther, 2016 Feb 09; 16(5). PMID: 26855028    Free PMC article.
Fine-tuning of CD8(+) T-cell effector functions by targeting the 2B4-CD48 interaction.
Anna Lissina, David R Ambrozak, +12 authors, Victor Appay.
Immunol Cell Biol, 2016 Feb 11; 94(6). PMID: 26860368
Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.
Maria Alsina, Markus Moehler, +2 authors, Josep Tabernero.
Target Oncol, 2016 Feb 18; 11(4). PMID: 26880697
Clinical impact of tumour biology in the management of gastroesophageal cancer.
Florian Lordick, Yelena Y Janjigian.
Nat Rev Clin Oncol, 2016 Mar 02; 13(6). PMID: 26925958    Free PMC article.
A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors.
Xiaojun Liu, Raghuveer Ranganathan, +8 authors, Edmund K Moon.
Cancer Res, 2016 Mar 17; 76(6). PMID: 26979791    Free PMC article.
Highly Cited.
Clinical utility of nivolumab in the treatment of advanced melanoma.
Ramsey Asmar, Jessica Yang, Richard D Carvajal.
Ther Clin Risk Manag, 2016 Mar 26; 12. PMID: 27013881    Free PMC article.
Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine.
Dmitriy Zamarin, Amir A Jazaeri.
Gynecol Oncol, 2016 Mar 27; 141(1). PMID: 27016233    Free PMC article.
Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition.
Liquan Gao, Chenran Zhang, +6 authors, Zhaofei Liu.
Theranostics, 2016 Mar 30; 6(5). PMID: 27022411    Free PMC article.
Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
Federica Cappuccini, Stephen Stribbling, +2 authors, Irina Redchenko.
Cancer Immunol Immunother, 2016 Apr 08; 65(6). PMID: 27052571    Free PMC article.
Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor.
Jens Schreiner, Daniela S Thommen, +16 authors, Alfred Zippelius.
Oncoimmunology, 2016 Apr 09; 5(2). PMID: 27057429    Free PMC article.
Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity.
Yongkui Li, Min Fang, +9 authors, Lin Wang.
Oncoimmunology, 2016 Apr 09; 5(2). PMID: 27057439    Free PMC article.
Vaccine-induced but not tumor-derived Interleukin-10 dictates the efficacy of Interleukin-10 blockade in therapeutic vaccination.
Diana Llopiz, Fernando Aranda, +5 authors, Pablo Sarobe.
Oncoimmunology, 2016 Apr 09; 5(2). PMID: 27057445    Free PMC article.
Repeated PD-1/PD-L1 monoclonal antibody administration induces fatal xenogeneic hypersensitivity reactions in a murine model of breast cancer.
Christine Mall, Gail D Sckisel, +8 authors, William J Murphy.
Oncoimmunology, 2016 Apr 09; 5(2). PMID: 27057446    Free PMC article.
Immunotherapy for cancer in the central nervous system: Current and future directions.
David C Binder, Andrew A Davis, Derek A Wainwright.
Oncoimmunology, 2016 Apr 09; 5(2). PMID: 27057463    Free PMC article.
Highly Cited. Review.
Cocktails for cancer with a measure of immunotherapy.
Heidi Ledford.
Nature, 2016 Apr 15; 532(7598). PMID: 27075078
Reversing T-cell Dysfunction and Exhaustion in Cancer.
Hassane M Zarour.
Clin Cancer Res, 2016 Apr 17; 22(8). PMID: 27084739    Free PMC article.
Highly Cited. Review.
A Truncated form of CD200 (CD200S) Expressed on Glioma Cells Prolonged Survival in a Rat Glioma Model by Induction of a Dendritic Cell-Like Phenotype in Tumor-Associated Macrophages.
Kana Kobayashi, Hajime Yano, +9 authors, Junya Tanaka.
Neoplasia, 2016 Apr 25; 18(4). PMID: 27108386    Free PMC article.
Immune Checkpoint Therapy and the Search for Predictive Biomarkers.
Padmanee Sharma.
Cancer J, 2016 Apr 26; 22(2). PMID: 27111900    Free PMC article.
Immune Checkpoint Therapies in Prostate Cancer.
Sangeeta Goswami, Ana Aparicio, Sumit K Subudhi.
Cancer J, 2016 Apr 26; 22(2). PMID: 27111907    Free PMC article.
A multi-antigen vaccine in combination with an immunotoxin targeting tumor-associated fibroblast for treating murine melanoma.
Jinxu Fang, Biliang Hu, +3 authors, Pin Wang.
Mol Ther Oncolytics, 2016 Apr 28; 3. PMID: 27119119    Free PMC article.
Cancer immunotherapy: the beginning of the end of cancer?
Sofia Farkona, Eleftherios P Diamandis, Ivan M Blasutig.
BMC Med, 2016 May 07; 14. PMID: 27151159    Free PMC article.
Highly Cited. Review.
Targeting immune checkpoints in unresectable metastatic cutaneous melanoma: a systematic review and meta-analysis of anti-CTLA-4 and anti-PD-1 agents trials.
Seongseok Yun, Nicole D Vincelette, +2 authors, Ivo Abraham.
Cancer Med, 2016 May 12; 5(7). PMID: 27167347    Free PMC article.
Systematic Review.
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer.
Ryan Montler, R Bryan Bell, +8 authors, Andrew Weinberg.
Clin Transl Immunology, 2016 May 20; 5(4). PMID: 27195113    Free PMC article.
Frequent PD-L1 expression in primary and metastatic penile squamous cell carcinoma: potential opportunities for immunotherapeutic approaches.
A M Udager, T-Y Liu, +16 authors, R Mehra.
Ann Oncol, 2016 May 25; 27(9). PMID: 27217541    Free PMC article.
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Weijie Ma, Barbara M Gilligan, Jianda Yuan, Tianhong Li.
J Hematol Oncol, 2016 May 29; 9(1). PMID: 27234522    Free PMC article.
Highly Cited. Review.
Metabolic regulation of immune responses: therapeutic opportunities.
Nadine Assmann, David K Finlay.
J Clin Invest, 2016 Jun 02; 126(6). PMID: 27249676    Free PMC article.
Key regulators of apoptosis execution as biomarker candidates in melanoma.
Emilie M Charles, Markus Rehm.
Mol Cell Oncol, 2014 Jul 01; 1(3). PMID: 27308353    Free PMC article.
Checkpoint Inhibitors in Head and Neck Cancer: Rationale, Clinical Activity, and Potential Biomarkers.
Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri.
Curr Treat Options Oncol, 2016 Jun 18; 17(8). PMID: 27315066
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
Maria I Carlo, Martin H Voss, Robert J Motzer.
Nat Rev Urol, 2016 Jun 22; 13(7). PMID: 27324121    Free PMC article.
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer.
S Chouaib, M Z Noman, K Kosmatopoulos, M A Curran.
Oncogene, 2016 Jun 28; 36(4). PMID: 27345407    Free PMC article.
Highly Cited. Review.
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges.
Chrisann Kyi, Michael A Postow.
Immunotherapy, 2016 Jun 29; 8(7). PMID: 27349981    Free PMC article.
Highly Cited. Review.
The role of pembrolizumab in the treatment of advanced non-small cell lung cancer.
Giuseppe Santabarbara, Paolo Maione, +2 authors, Cesare Gridelli.
Ann Transl Med, 2016 Jul 08; 4(11). PMID: 27386489    Free PMC article.
GRIM19 ameliorates acute graft-versus-host disease (GVHD) by modulating Th17 and Treg cell balance through down-regulation of STAT3 and NF-AT activation.
Min-Jung Park, Seung Hoon Lee, +4 authors, Mi- La Cho.
J Transl Med, 2016 Jul 09; 14(1). PMID: 27391226    Free PMC article.
Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors.
Eric D Brooks, Jonathan E Schoenhals, +4 authors, James W Welsh.
Cancer J, 2016 Jul 22; 22(4). PMID: 27441745    Free PMC article.
PD-1 blockade enhances the vaccination-induced immune response in glioma.
Joseph P Antonios, Horacio Soto, +9 authors, Robert M Prins.
JCI Insight, 2016 Jul 28; 1(10). PMID: 27453950    Free PMC article.
Highly Cited.
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition.
Leonid Cherkassky, Aurore Morello, +5 authors, Prasad S Adusumilli.
J Clin Invest, 2016 Jul 28; 126(8). PMID: 27454297    Free PMC article.
Highly Cited.
SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade.
Wei Xue, Rachael L Metheringham, +5 authors, Lindy G Durrant.
Oncoimmunology, 2016 Jul 30; 5(6). PMID: 27471648    Free PMC article.
Update on the challenges and recent advances in cancer immunotherapy.
Gianfranco Baronzio, Gurdev Parmar, +4 authors, Mikhail Kiselevsky.
Immunotargets Ther, 2013 Jan 01; 2. PMID: 27471687    Free PMC article.
The role of regulatory T cells in cancer immunology.
Theresa L Whiteside.
Immunotargets Ther, 2015 Jan 01; 4. PMID: 27471721    Free PMC article.
Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.
Joline S J Lim, Ross A Soo.
Ther Adv Respir Dis, 2016 Aug 03; 10(5). PMID: 27480166    Free PMC article.
Immunotherapy of advanced renal cell carcinoma: Current and future therapies.
David Gill, Andrew W Hahn, Guru Sonpavde, Neeraj Agarwal.
Hum Vaccin Immunother, 2016 Aug 06; 12(12). PMID: 27494417    Free PMC article.
Interdependent IL-7 and IFN-γ signalling in T-cell controls tumour eradication by combined α-CTLA-4+α-PD-1 therapy.
Lewis Zhichang Shi, Tihui Fu, +7 authors, Padmanee Sharma.
Nat Commun, 2016 Aug 09; 7. PMID: 27498556    Free PMC article.
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Benjamin Herzberg, Meghan J Campo, Justin F Gainor.
Oncologist, 2016 Aug 19; 22(1). PMID: 27534574    Free PMC article.
Precision glycocalyx editing as a strategy for cancer immunotherapy.
Han Xiao, Elliot C Woods, Petar Vukojicic, Carolyn R Bertozzi.
Proc Natl Acad Sci U S A, 2016 Aug 24; 113(37). PMID: 27551071    Free PMC article.
Highly Cited.
Inflammation-Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti-PD1 Antibody.
Chao Wang, Wujin Sun, +2 authors, Zhen Gu.
Adv Mater, 2016 Oct 21; 28(40). PMID: 27558441    Free PMC article.
Forced co-expression of IL-21 and IL-7 in whole-cell cancer vaccines promotes antitumor immunity.
Yang-Zhuo Gu, Chuan-Wen Fan, +7 authors, Yu-Quan Wei.
Sci Rep, 2016 Aug 31; 6. PMID: 27571893    Free PMC article.
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment.
Hazem El-Osta, Kamran Shahid, Glenn M Mills, Prakash Peddi.
Onco Targets Ther, 2016 Aug 31; 9. PMID: 27574451    Free PMC article.
Second-generation inhibitors of Bruton tyrosine kinase.
Jingjing Wu, Christina Liu, Stella T Tsui, Delong Liu.
J Hematol Oncol, 2016 Sep 04; 9(1). PMID: 27590878    Free PMC article.
Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology.
Mark J Selby, John J Engelhardt, +11 authors, Alan J Korman.
PLoS One, 2016 Sep 10; 11(9). PMID: 27610613    Free PMC article.
Highly Cited.
Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy.
Hasan Rehman, Ann W Silk, Michael P Kane, Howard L Kaufman.
J Immunother Cancer, 2016 Sep 24; 4. PMID: 27660707    Free PMC article.
Highly Cited.
Adjuvants for peptide-based cancer vaccines.
Hiep Khong, Willem W Overwijk.
J Immunother Cancer, 2016 Sep 24; 4. PMID: 27660710    Free PMC article.
Immune checkpoint and inflammation as therapeutic targets in pancreatic carcinoma.
Shiro Kimbara, Shunsuke Kondo.
World J Gastroenterol, 2016 Sep 28; 22(33). PMID: 27672267    Free PMC article.
TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies.
Tristan Courau, Djamel Nehar-Belaid, +5 authors, David Klatzmann.
JCI Insight, 2016 Oct 05; 1(9). PMID: 27699271    Free PMC article.
Neoantigens in immunotherapy and personalized vaccines: Implications for head and neck squamous cell carcinoma.
Paul Zolkind, Gavin P Dunn, +3 authors, Ravindra Uppaluri.
Oral Oncol, 2016 Oct 19; 71. PMID: 27751760    Free PMC article.
Targeting immune checkpoints in malignant glioma.
Xuhao Zhang, Shan Zhu, +3 authors, Jingtao Chen.
Oncotarget, 2016 Oct 21; 8(4). PMID: 27756892    Free PMC article.
Photothermal therapy with immune-adjuvant nanoparticles together with checkpoint blockade for effective cancer immunotherapy.
Qian Chen, Ligeng Xu, +3 authors, Zhuang Liu.
Nat Commun, 2016 Oct 22; 7. PMID: 27767031    Free PMC article.
Highly Cited.
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedside.
Jingjing Wu, Mingzhi Zhang, Delong Liu.
Oncotarget, 2016 Oct 25; 8(4). PMID: 27776353    Free PMC article.
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.
Genevieve M Weir, Olga Hrytsenko, +3 authors, Marc Mansour.
J Immunother Cancer, 2016 Oct 26; 4. PMID: 27777777    Free PMC article.
Approaches to modernize the combination drug development paradigm.
Daphne Day, Lillian L Siu.
Genome Med, 2016 Oct 30; 8(1). PMID: 27793177    Free PMC article.
An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy.
Yichao Chen, Rui Xia, +10 authors, Song Li.
Nat Commun, 2016 Nov 08; 7. PMID: 27819653    Free PMC article.
SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors.
Wei Xue, Victoria A Brentville, +4 authors, Lindy G Durrant.
Oncotarget, 2016 Nov 09; 7(50). PMID: 27825115    Free PMC article.
Cell-Intrinsic Barriers of T Cell-Based Immunotherapy.
Hazem E Ghoneim, Anthony E Zamora, Paul G Thomas, Ben A Youngblood.
Trends Mol Med, 2016 Nov 09; 22(12). PMID: 27825667    Free PMC article.
Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.
Soumaya Karaki, Marie Anson, +4 authors, Eric Tartour.
Vaccines (Basel), 2016 Nov 10; 4(4). PMID: 27827885    Free PMC article.
Combination Approaches with Immune-Checkpoint Blockade in Cancer Therapy.
Maarten Swart, Inge Verbrugge, Joost B Beltman.
Front Oncol, 2016 Nov 17; 6. PMID: 27847783    Free PMC article.
Highly Cited. Review.
The Future Prospects of Immune Therapy in Gastric and Esophageal Adenocarcinoma.
Walid L Shaib, Jean Paul A Nammour, +2 authors, Nabil F Saba.
J Clin Med, 2016 Nov 18; 5(11). PMID: 27854242    Free PMC article.
Model-Based Characterization of the Pharmacokinetics of Pembrolizumab: A Humanized Anti-PD-1 Monoclonal Antibody in Advanced Solid Tumors.
M Ahamadi, T Freshwater, +6 authors, J A Stone.
CPT Pharmacometrics Syst Pharmacol, 2016 Nov 20; 6(1). PMID: 27863186    Free PMC article.
Immunotherapy in small-cell lung cancer: at what point are we?
Antonio Rossi.
Ann Transl Med, 2016 Nov 22; 4(Suppl 1). PMID: 27867973    Free PMC article.
Hijacker of the Antitumor Immune Response: Autophagy Is Showing Its Worst Facet.
Elodie Viry, Muhammad Zaeem Noman, +6 authors, Bassam Janji.
Front Oncol, 2016 Dec 06; 6. PMID: 27917371    Free PMC article.
Growth and metastasis of lung adenocarcinoma is potentiated by BMP4-mediated immunosuppression.
Limo Chen, Xiaohui Yi, +13 authors, Don L Gibbons.
Oncoimmunology, 2016 Dec 22; 5(11). PMID: 27999749    Free PMC article.
A New VISTA on combination therapy for negative checkpoint regulator blockade.
Jie Deng, Isabelle Le Mercier, Anna Kuta, Randolph J Noelle.
J Immunother Cancer, 2016 Dec 30; 4. PMID: 28031817    Free PMC article.
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
David J Byun, Jedd D Wolchok, Lynne M Rosenberg, Monica Girotra.
Nat Rev Endocrinol, 2017 Jan 21; 13(4). PMID: 28106152    Free PMC article.
Highly Cited. Review.
New Combination Strategies Using Programmed Cell Death 1/Programmed Cell Death Ligand 1 Checkpoint Inhibitors as a Backbone.
Siwen Hu-Lieskovan, Antoni Ribas.
Cancer J, 2017 Jan 24; 23(1). PMID: 28114250    Free PMC article.
Clinical Dosing Regimen of Selinexor Maintains Normal Immune Homeostasis and T-cell Effector Function in Mice: Implications for Combination with Immunotherapy.
Paul M Tyler, Mariah M Servos, +6 authors, Stephanie K Dougan.
Mol Cancer Ther, 2017 Feb 06; 16(3). PMID: 28148714    Free PMC article.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas.
Cell, 2017 Feb 12; 168(4). PMID: 28187290    Free PMC article.
Highly Cited. Review.
Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer.
Ruea-Yea Huang, Ariel Francois, +2 authors, Kunle Odunsi.
Oncoimmunology, 2017 Feb 16; 6(1). PMID: 28197366    Free PMC article.
Highly Cited.
Cardiovascular Toxicities Associated with Cancer Immunotherapies.
Daniel Y Wang, Gosife Donald Okoye, +2 authors, Javid J Moslehi.
Curr Cardiol Rep, 2017 Feb 22; 19(3). PMID: 28220466
Highly Cited. Review.
Combination immunotherapy: a road map.
Patrick A Ott, F Stephen Hodi, +2 authors, Jedd D Wolchok.
J Immunother Cancer, 2017 Feb 28; 5. PMID: 28239469    Free PMC article.
Highly Cited. Review.
The Role of Immune Checkpoint Inhibition in the Treatment of Brain Tumors.
Andrew S Luksik, Russell Maxwell, Tomas Garzon-Muvdi, Michael Lim.
Neurotherapeutics, 2017 Mar 05; 14(4). PMID: 28258545    Free PMC article.
Immunoregulatory functions of VISTA.
Elizabeth C Nowak, J Louise Lines, +7 authors, Randolph J Noelle.
Immunol Rev, 2017 Mar 05; 276(1). PMID: 28258694    Free PMC article.
Highly Cited. Review.
Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?
Jordi Remon, Benjamin Besse, Jean-Charles Soria.
BMC Med, 2017 Mar 14; 15(1). PMID: 28285592    Free PMC article.
Reinvigorating Exhausted T Cells by Blockade of the PD-1 Pathway.
Junghwa Lee, Eunseon Ahn, Haydn T Kissick, Rafi Ahmed.
For Immunopathol Dis Therap, 2015 Jan 01; 6(1-2). PMID: 28286692    Free PMC article.
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
Vikram R Juneja, Kathleen A McGuire, +5 authors, Arlene H Sharpe.
J Exp Med, 2017 Mar 18; 214(4). PMID: 28302645    Free PMC article.
Highly Cited.
Mechanistic and pharmacologic insights on immune checkpoint inhibitors.
Randy F Sweis, Jason J Luke.
Pharmacol Res, 2017 Mar 23; 120. PMID: 28323141    Free PMC article.
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.
Jennifer D Moy, Jessica M Moskovitz, Robert L Ferris.
Eur J Cancer, 2017 Mar 23; 76. PMID: 28324750    Free PMC article.
Retroviral Replicating Vector Delivery of miR-PDL1 Inhibits Immune Checkpoint PDL1 and Enhances Immune Responses In Vitro.
Amy H Lin, Christopher G Twitty, +5 authors, Douglas J Jolly.
Mol Ther Nucleic Acids, 2017 Mar 23; 6. PMID: 28325288    Free PMC article.
The Granulocyte Progenitor Stage Is a Key Target of IRF8-Mediated Regulation of Myeloid-Derived Suppressor Cell Production.
Colleen S Netherby, Michelle N Messmer, +6 authors, Scott I Abrams.
J Immunol, 2017 Mar 31; 198(10). PMID: 28356386    Free PMC article.
Targeted agents and immunotherapies: optimizing outcomes in melanoma.
Jason J Luke, Keith T Flaherty, Antoni Ribas, Georgina V Long.
Nat Rev Clin Oncol, 2017 Apr 05; 14(8). PMID: 28374786
Highly Cited. Review.
Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment.
Azharuddin Sajid Syed Khaja, Salman M Toor, +4 authors, Eyad Elkord.
Oncotarget, 2017 Apr 08; 8(20). PMID: 28388539    Free PMC article.
Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy.
Song Xue, Man Hu, Veena Iyer, Jinming Yu.
J Hematol Oncol, 2017 Apr 09; 10(1). PMID: 28388955    Free PMC article.
Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors.
Ornella Franzese, Francesco Torino, +5 authors, Stefania D'Atri.
Oncotarget, 2017 Apr 14; 8(25). PMID: 28404974    Free PMC article.
Immunotherapeutic approaches for hepatocellular carcinoma.
Vito Longo, Antonio Gnoni, +10 authors, Oronzo Brunetti.
Oncotarget, 2017 Apr 20; 8(20). PMID: 28420805    Free PMC article.
Increasing the safety and efficacy of chimeric antigen receptor T cell therapy.
Hua Li, Yangbing Zhao.
Protein Cell, 2017 Apr 24; 8(8). PMID: 28434147    Free PMC article.
Potent antitumour activity of interleukin-2-Fc fusion proteins requires Fc-mediated depletion of regulatory T-cells.
Rodrigo Vazquez-Lombardi, Claudia Loetsch, +8 authors, Daniel Christ.
Nat Commun, 2017 May 13; 8. PMID: 28497796    Free PMC article.
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
Joanna Mangana, Phil F Cheng, +10 authors, Reinhard Dummer.
Melanoma Res, 2017 May 17; 27(4). PMID: 28509765    Free PMC article.
Unravelling the biology of SCLC: implications for therapy.
Joshua K Sabari, Benjamin H Lok, +2 authors, Charles M Rudin.
Nat Rev Clin Oncol, 2017 May 24; 14(9). PMID: 28534531    Free PMC article.
Highly Cited. Review.
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
Silvia Martin Lluesma, Anita Wolfer, Alexandre Harari, Lana E Kandalaft.
Biomedicines, 2017 May 26; 4(2). PMID: 28536377    Free PMC article.
Immune and molecular correlates in melanoma treated with immune checkpoint blockade.
Elizabeth H Byrne, David E Fisher.
Cancer, 2017 May 26; 123(S11). PMID: 28543699    Free PMC article.
Increased serum level of soluble interleukin-2 receptor is associated with a worse response of metastatic clear cell renal cell carcinoma to interferon alpha and sequential VEGF-targeting therapy.
Akinori Nukui, Akinori Masuda, +3 authors, Takao Kamai.
BMC Cancer, 2017 May 27; 17(1). PMID: 28545581    Free PMC article.
Delivering safer immunotherapies for cancer.
Lauren Milling, Yuan Zhang, Darrell J Irvine.
Adv Drug Deliv Rev, 2017 May 27; 114. PMID: 28545888    Free PMC article.
Highly Cited. Review.
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy.
Roberta Mazzone, Clemens Zwergel, Antonello Mai, Sergio Valente.
Clin Epigenetics, 2017 Jun 03; 9. PMID: 28572863    Free PMC article.
Highly Cited. Review.
PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells.
Carmen Stecher, Claire Battin, +5 authors, Peter Steinberger.
Front Immunol, 2017 Jun 08; 8. PMID: 28588576    Free PMC article.
Intratumoral FoxP3+Helios+ Regulatory T Cells Upregulating Immunosuppressive Molecules Are Expanded in Human Colorectal Cancer.
Azharuddin Sajid Syed Khaja, Salman M Toor, +2 authors, Eyad Elkord.
Front Immunol, 2017 Jun 13; 8. PMID: 28603527    Free PMC article.
Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab.
C Brüggemann, M C Kirchberger, +14 authors, L Heinzerling.
J Cancer Res Clin Oncol, 2017 Jun 16; 143(10). PMID: 28616701
Potential Contributions of Antioxidants to Cancer Therapy: Immunomodulation and Radiosensitization.
Anita Thyagarajan, Ravi P Sahu.
Integr Cancer Ther, 2017 Jun 20; 17(2). PMID: 28627256    Free PMC article.
[Prospect and Current Situation of Immune Checkpoint Inhibitors 
in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients].
Haiyang Wang, Xiaoqing Yu, Yun Fan.
Zhongguo Fei Ai Za Zhi, 2017 Jun 24; 20(6). PMID: 28641702    Free PMC article.
CTLA-4-mediated posttranslational modifications direct cytotoxic T-lymphocyte differentiation.
Holger Lingel, Josef Wissing, +7 authors, Monika C Brunner-Weinzierl.
Cell Death Differ, 2017 Jun 24; 24(10). PMID: 28644433    Free PMC article.
ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.
Mathieu F Chevalier, Sara Trabanelli, +14 authors, Laurent Derré.
J Clin Invest, 2017 Jun 27; 127(8). PMID: 28650339    Free PMC article.
Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Chunyan Hao, Jinhui Tian, +3 authors, Bingdong Zhu.
Medicine (Baltimore), 2017 Jun 29; 96(26). PMID: 28658143    Free PMC article.
Systematic Review.
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells.
Mohammad Rashidian, Jessica R Ingram, +11 authors, Hidde L Ploegh.
J Exp Med, 2017 Jul 02; 214(8). PMID: 28666979    Free PMC article.
Highly Cited.
Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Casey R Ager, Matthew J Reilley, +3 authors, Michael A Curran.
Cancer Immunol Res, 2017 Jul 05; 5(8). PMID: 28674082    Free PMC article.
Highly Cited.
Optimal Therapy of Advanced Stage Mesothelioma.
Maria M J Disselhorst, Sjaak J A Burgers, Paul Baas.
Curr Treat Options Oncol, 2017 Jul 07; 18(8). PMID: 28681207
Induction of a Regulatory Phenotype in CD3+ CD4+ HLA-DR+ T Cells after Allogeneic Mixed Lymphocyte Culture; Indications of Both Contact-Dependent and -Independent Activation.
Anne Louise Schacht Revenfeld, Rikke Bæk, +2 authors, Allan Stensballe.
Int J Mol Sci, 2017 Jul 25; 18(7). PMID: 28737722    Free PMC article.
Toward Precision Radiotherapy for Use with Immune Checkpoint Blockers.
Claire Vanpouille-Box, Silvia C Formenti, Sandra Demaria.
Clin Cancer Res, 2017 Jul 29; 24(2). PMID: 28751442    Free PMC article.
Highly Cited. Review.
New treatment options for metastatic renal cell carcinoma.
Alejo Rodriguez-Vida, Thomas E Hutson, Joaquim Bellmunt, Michiel H Strijbos.
ESMO Open, 2017 Aug 02; 2(2). PMID: 28761748    Free PMC article.
Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.
Hojabr Kakavand, Louise A Jackett, +7 authors, Richard A Scolyer.
Mod Pathol, 2017 Aug 05; 30(12). PMID: 28776578
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Spencer C Wei, Jacob H Levine, +8 authors, James P Allison.
Cell, 2017 Aug 15; 170(6). PMID: 28803728    Free PMC article.
Highly Cited.
Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.
Dylan J Martini, Aly-Khan A Lalani, +5 authors, Toni K Choueiri.
J Immunother Cancer, 2017 Aug 16; 5(1). PMID: 28807048    Free PMC article.
Agonist anti-GITR antibody significantly enhances the therapeutic efficacy of Listeria monocytogenes-based immunotherapy.
Rajeev Shrimali, Shamim Ahmad, +7 authors, Samir N Khleif.
J Immunother Cancer, 2017 Aug 16; 5(1). PMID: 28807056    Free PMC article.
Macrophage Polarization Contributes to Glioblastoma Eradication by Combination Immunovirotherapy and Immune Checkpoint Blockade.
Dipongkor Saha, Robert L Martuza, Samuel D Rabkin.
Cancer Cell, 2017 Aug 16; 32(2). PMID: 28810147    Free PMC article.
Highly Cited.
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study.
Thomas Powles, Peter H O'Donnell, +16 authors, Noah M Hahn.
JAMA Oncol, 2017 Aug 18; 3(9). PMID: 28817753    Free PMC article.
Highly Cited.
β-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy.
Mark J Bucsek, Guanxi Qiao, +11 authors, Elizabeth A Repasky.
Cancer Res, 2017 Aug 19; 77(20). PMID: 28819022    Free PMC article.
TIM-4 Identifies IFN-γ-Expressing Proinflammatory B Effector 1 Cells That Promote Tumor and Allograft Rejection.
Qing Ding, Kanishka Mohib, Vijay K Kuchroo, David M Rothstein.
J Immunol, 2017 Aug 30; 199(7). PMID: 28848066    Free PMC article.
The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches.
Panagiota Economopoulou, Ioannis Kotsantis, Amanda Psyrri.
ESMO Open, 2017 Aug 30; 1(6). PMID: 28848660    Free PMC article.
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.
Daphne Day, Arta M Monjazeb, +4 authors, Marcus O Butler.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864726    Free PMC article.
Immune checkpoint inhibitors in cancer therapy.
Eika S Webb, Peng Liu, +3 authors, Yao-He Wang.
J Biomed Res, 2017 Sep 04; 32(5). PMID: 28866656    Free PMC article.
Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis.
Adam K Karlsson, Sohag N Saleh.
Clin Cosmet Investig Dermatol, 2017 Sep 09; 10. PMID: 28883738    Free PMC article.
Tumor necrosis factor alpha secreted from oral squamous cell carcinoma contributes to cancer pain and associated inflammation.
Nicole N Scheff, Yi Ye, +5 authors, Brian L Schmidt.
Pain, 2017 Sep 09; 158(12). PMID: 28885456    Free PMC article.
NF-κB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer.
Yenkel Grinberg-Bleyer, Hyunju Oh, +7 authors, Sankar Ghosh.
Cell, 2017 Sep 09; 170(6). PMID: 28886380    Free PMC article.
Highly Cited.
De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors.
Anna Johansson-Percival, Bo He, +5 authors, Ruth Ganss.
Nat Immunol, 2017 Sep 12; 18(11). PMID: 28892469
Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma.
David Kung-Chun Chiu, Aki Pui-Wah Tse, +9 authors, Carmen Chak-Lui Wong.
Nat Commun, 2017 Sep 13; 8(1). PMID: 28894087    Free PMC article.
Highly Cited.
Tumor location impacts immune response in mouse models of colon cancer.
Xianda Zhao, Lihua Li, Timothy K Starr, Subbaya Subramanian.
Oncotarget, 2017 Sep 15; 8(33). PMID: 28903381    Free PMC article.
Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
Thomas B Huffaker, Soh-Hyun Lee, +11 authors, Ryan M O'Connell.
J Biol Chem, 2017 Sep 16; 292(45). PMID: 28912267    Free PMC article.
Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.
Sulsal Haque, Mahender Yellu, Jaskirat Randhawa, Nooshin Hashemi-Sadraei.
Drug Des Devel Ther, 2017 Sep 19; 11. PMID: 28919706    Free PMC article.
Combination central tolerance and peripheral checkpoint blockade unleashes antimelanoma immunity.
Pearl Bakhru, Meng-Lei Zhu, +14 authors, Maureen A Su.
JCI Insight, 2017 Sep 22; 2(18). PMID: 28931755    Free PMC article.
Inactivated Sendai virus particle upregulates cancer cell expression of intercellular adhesion molecule-1 and enhances natural killer cell sensitivity on cancer cells.
Simin Li, Tomoyuki Nishikawa, Yasufumi Kaneda.
Cancer Sci, 2017 Sep 26; 108(12). PMID: 28945328    Free PMC article.
Advances on immunotherapy in genitourinary and renal cell carcinoma.
Gregory P Botta, Eric Granowicz, Carrie Costantini.
Transl Cancer Res, 2017 Oct 03; 6(1). PMID: 28966917    Free PMC article.
PD-1 Blockade Prevents the Development and Progression of Carcinogen-Induced Oral Premalignant Lesions.
Jin Wang, Tongxin Xie, +5 authors, Carlos Caulin.
Cancer Prev Res (Phila), 2017 Oct 12; 10(12). PMID: 29018057    Free PMC article.
Challenging the standard of care in advanced melanoma: focus on pembrolizumab.
Raghad M Abdul-Karim, C Lance Cowey.
Cancer Manag Res, 2017 Oct 14; 9. PMID: 29026335    Free PMC article.
Coinhibitory Receptor Expression and Immune Checkpoint Blockade: Maintaining a Balance in CD8+ T Cell Responses to Chronic Viral Infections and Cancer.
Isobel S Okoye, Michael Houghton, +2 authors, Shokrollah Elahi.
Front Immunol, 2017 Oct 17; 8. PMID: 29033936    Free PMC article.
Hormonal vitamin D up-regulates tissue-specific PD-L1 and PD-L2 surface glycoprotein expression in humans but not mice.
Vassil Dimitrov, Manuella Bouttier, +7 authors, John H White.
J Biol Chem, 2017 Oct 25; 292(50). PMID: 29061851    Free PMC article.
An Archaeosome-Adjuvanted Vaccine and Checkpoint Inhibitor Therapy Combination Significantly Enhances Protection from Murine Melanoma.
Felicity C Stark, Risini D Weeratna, +4 authors, Lakshmi Krishnan.
Vaccines (Basel), 2017 Oct 27; 5(4). PMID: 29072624    Free PMC article.
Development of a Curative Therapeutic Vaccine (TheraVac) for the Treatment of Large Established Tumors.
Yingjie Nie, De Yang, +4 authors, Joost J Oppenheim.
Sci Rep, 2017 Oct 29; 7(1). PMID: 29079801    Free PMC article.
Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids.
Russell W Jenkins, Amir R Aref, +81 authors, David A Barbie.
Cancer Discov, 2017 Nov 05; 8(2). PMID: 29101162    Free PMC article.
Highly Cited.
Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia.
Sanah Sajawal, Sarah L Mackie, Peter Hillmen, Dennis McGonagle.
BMJ Case Rep, 2017 Nov 11; 2017. PMID: 29122897    Free PMC article.
Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance.
Mark Owyong, Niloufar Hosseini-Nassab, +4 authors, Bryan Ronain Smith.
Drug Resist Updat, 2017 Nov 18; 33-35. PMID: 29145972    Free PMC article.
Cure in Advanced Renal Cell Cancer: Is It an Achievable Goal?
Dhanusha Sabanathan, John J Park, +3 authors, Howard Gurney.
Oncologist, 2017 Nov 18; 22(12). PMID: 29146617    Free PMC article.
Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas.
Hannah Schneider, Birthe Lohmann, +6 authors, Michael Weller.
Oncotarget, 2017 Nov 21; 8(50). PMID: 29152068    Free PMC article.
Mixed Signals: Co-Stimulation in Invariant Natural Killer T Cell-Mediated Cancer Immunotherapy.
Susannah C Shissler, Michael S Lee, Tonya J Webb.
Front Immunol, 2017 Nov 23; 8. PMID: 29163518    Free PMC article.
Targeting immune checkpoints in breast cancer: an update of early results.
Cinzia Solinas, Andrea Gombos, +3 authors, Laurence Buisseret.
ESMO Open, 2017 Nov 28; 2(5). PMID: 29177095    Free PMC article.
Management of intracranial melanomas in the era of precision medicine.
Grace J Young, Wenya Linda Bi, +3 authors, Ian F Dunn.
Oncotarget, 2017 Nov 29; 8(51). PMID: 29179523    Free PMC article.
Screening and antitumor effect of an anti‑CTLA‑4 nanobody.
Ruirong Wan, Aiqun Liu, +9 authors, Xiaoling Lu.
Oncol Rep, 2017 Dec 06; 39(2). PMID: 29207143    Free PMC article.
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy.
Ryuma Tokunaga, Wu Zhang, +6 authors, Heinz-Josef Lenz.
Cancer Treat Rev, 2017 Dec 06; 63. PMID: 29207310    Free PMC article.
Highly Cited. Review.
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet.
Anna C Filley, Mario Henriquez, Mahua Dey.
Oncotarget, 2017 Dec 07; 8(53). PMID: 29207684    Free PMC article.
Highly Cited. Review.
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract.
Michael Dougan.
Front Immunol, 2017 Dec 13; 8. PMID: 29230210    Free PMC article.
Highly Cited. Review.
Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity.
Ashley V Kroll, Ronnie H Fang, +8 authors, Liangfang Zhang.
Adv Mater, 2017 Dec 15; 29(47). PMID: 29239517    Free PMC article.
Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy.
Anne-Sophie Gautron, Alexandre Juillerat, +5 authors, Laurent Poirot.
Mol Ther Nucleic Acids, 2017 Dec 17; 9. PMID: 29246309    Free PMC article.
Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT.
Elizabeth K Duperret, Megan C Wise, +8 authors, David B Weiner.
Mol Ther, 2017 Dec 19; 26(2). PMID: 29249395    Free PMC article.
Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma.
Yutaka Takahashi, Tomohiro Yasui, +7 authors, Kazuhiko Ogawa.
PLoS One, 2017 Dec 19; 12(12). PMID: 29253865    Free PMC article.
PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
Zijun Y Xu-Monette, Mingzhi Zhang, Jianyong Li, Ken H Young.
Front Immunol, 2017 Dec 20; 8. PMID: 29255458    Free PMC article.
Highly Cited. Review.
Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer.
Lina Liu, Yuhua Wang, +4 authors, Leaf Huang.
Mol Ther, 2017 Dec 21; 26(1). PMID: 29258739    Free PMC article.
A novel cancer vaccine with the ability to simultaneously produce anti-PD-1 antibody and GM-CSF in cancer cells and enhance Th1-biased antitumor immunity.
Hongwei Tian, Gang Shi, +12 authors, Hongxin Deng.
Signal Transduct Target Ther, 2017 Dec 22; 1. PMID: 29263903    Free PMC article.
Novel immunotherapy approaches for metastatic urothelial and renal cell carcinoma.
Zhiying Shao, Andrew Z Wang, Daniel J George, Tian Zhang.
Asian J Urol, 2016 Oct 01; 3(4). PMID: 29264195    Free PMC article.
T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.
Tamara Hilmenyuk, Carla A Ruckstuhl, +7 authors, Adrian F Ochsenbein.
Oncoimmunology, 2018 Jan 04; 7(1). PMID: 29296517    Free PMC article.
Inhibitors of the PD-1 Pathway in Tumor Therapy.
Martin W LaFleur, Yuki Muroyama, Charles G Drake, Arlene H Sharpe.
J Immunol, 2018 Jan 10; 200(2). PMID: 29311378    Free PMC article.
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Erhao Zhang, Jieyi Gu, Hanmei Xu.
Mol Cancer, 2018 Jan 14; 17(1). PMID: 29329591    Free PMC article.
Improving immune-vascular crosstalk for cancer immunotherapy.
Yuhui Huang, Betty Y S Kim, +3 authors, Wen Jiang.
Nat Rev Immunol, 2018 Jan 16; 18(3). PMID: 29332937    Free PMC article.
Highly Cited. Review.
Anti-IL-10-mediated Enhancement of Antitumor Efficacy of a Dendritic Cell-targeting MIP3α-gp100 Vaccine in the B16F10 Mouse Melanoma Model Is Dependent on Type I Interferons.
James T Gordy, Kun Luo, +2 authors, Richard B Markham.
J Immunother, 2018 Jan 16; 41(4). PMID: 29334492    Free PMC article.
LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer.
Masoud F Tavazoie, Ilana Pollack, +21 authors, Sohail F Tavazoie.
Cell, 2018 Jan 18; 172(4). PMID: 29336888    Free PMC article.
Highly Cited.
CNS side effects of immune checkpoint inhibitors: preclinical models, genetics and multimodality therapy.
Gwendolyn J McGinnis, Jacob Raber.
Immunotherapy, 2018 Jan 18; 9(11). PMID: 29338610    Free PMC article.
The biology and management of non-small cell lung cancer.
Roy S Herbst, Daniel Morgensztern, Chris Boshoff.
Nature, 2018 Jan 25; 553(7689). PMID: 29364287
Highly Cited. Review.
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.
Sandra P D'Angelo, Michelle R Mahoney, +8 authors, Howard Streicher.
Lancet Oncol, 2018 Jan 27; 19(3). PMID: 29370992    Free PMC article.
Highly Cited.
Cell death-based treatment of lung adenocarcinoma.
Tatiana V Denisenko, Inna N Budkevich, Boris Zhivotovsky.
Cell Death Dis, 2018 Jan 27; 9(2). PMID: 29371589    Free PMC article.
Highly Cited. Review.
PD-L1 checkpoint inhibition and anti-CTLA-4 whole tumor cell vaccination counter adaptive immune resistance: A mouse neuroblastoma model that mimics human disease.
Priya Srinivasan, Xiaofang Wu, +2 authors, Anthony D Sandler.
PLoS Med, 2018 Jan 30; 15(1). PMID: 29377881    Free PMC article.
Regulation of chitinase-3-like-1 in T cell elicits Th1 and cytotoxic responses to inhibit lung metastasis.
Do-Hyun Kim, Hong-Jai Park, +10 authors, Je-Min Choi.
Nat Commun, 2018 Feb 07; 9(1). PMID: 29403003    Free PMC article.
Polymeric microneedles for transdermal protein delivery.
Yanqi Ye, Jicheng Yu, +2 authors, Zhen Gu.
Adv Drug Deliv Rev, 2018 Feb 07; 127. PMID: 29408182    Free PMC article.
Bispecific tumor-penetrating protein anti-EGFR-iRGD efficiently enhances the infiltration of lymphocytes in gastric cancer.
Anqing Zhu, Huizi Sha, +11 authors, Baorui Liu.
Am J Cancer Res, 2018 Feb 09; 8(1). PMID: 29416923    Free PMC article.
Inhibition of tumor growth by cancer vaccine combined with metronomic chemotherapy and anti-PD-1 in a pre-clinical setting.
Annacarmen Petrizzo, Angela Mauriello, +11 authors, Luigi Buonaguro.
Oncotarget, 2018 Feb 10; 9(3). PMID: 29423067    Free PMC article.
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.
Jeffrey M Clarke, Daniel J George, Stacey Lisi, April K S Salama.
Target Oncol, 2018 Feb 15; 13(1). PMID: 29441437
Targeting Cytokine Therapy to the Pancreatic Tumor Microenvironment Using PD-L1-Specific VHHs.
Michael Dougan, Jessica R Ingram, +12 authors, Stephanie K Dougan.
Cancer Immunol Res, 2018 Feb 21; 6(4). PMID: 29459478    Free PMC article.
Transcriptional Repressor HIC1 Contributes to Suppressive Function of Human Induced Regulatory T Cells.
Ubaid Ullah, Syed Bilal Ahmad Andrabi, +14 authors, Riitta Lahesmaa.
Cell Rep, 2018 Feb 22; 22(8). PMID: 29466736    Free PMC article.
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy.
Yared Hailemichael, Amber Woods, +17 authors, Willem W Overwijk.
J Clin Invest, 2018 Feb 27; 128(4). PMID: 29480817    Free PMC article.
Highly Cited.
Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).
Jorge Augusto Borin Scutti.
Int J Oncol, 2018 Feb 28; 52(4). PMID: 29484440    Free PMC article.
Subcutaneous Nanodisc Vaccination with Neoantigens for Combination Cancer Immunotherapy.
Rui Kuai, Xiaoqi Sun, +3 authors, James J Moon.
Bioconjug Chem, 2018 Feb 28; 29(3). PMID: 29485848    Free PMC article.
PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity.
Sarah L Buchan, Mohannad Fallatah, +8 authors, Aymen Al-Shamkhani.
Clin Cancer Res, 2018 Mar 09; 24(10). PMID: 29514845    Free PMC article.
Optimizing Tumor Microenvironment for Cancer Immunotherapy: β-Glucan-Based Nanoparticles.
Mei Zhang, Julian A Kim, Alex Yee-Chen Huang.
Front Immunol, 2018 Mar 15; 9. PMID: 29535722    Free PMC article.
Multifunctional (3-in-1) cancer theranostics applications of hydroxyquinoline-appended polyfluorene nanoparticles.
Sayan Roy Chowdhury, Sudip Mukherjee, +2 authors, Parameswar Krishnan Iyer.
Chem Sci, 2018 Mar 24; 8(11). PMID: 29568419    Free PMC article.
Current Strategies to Enhance Anti-Tumour Immunity.
Katherine W Cook, Lindy G Durrant, Victoria A Brentville.
Biomedicines, 2018 Mar 24; 6(2). PMID: 29570634    Free PMC article.
Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy.
J D Nosanchuk, A Jeyakumar, +14 authors, E Dadachova.
Sci Rep, 2018 Apr 05; 8(1). PMID: 29615812    Free PMC article.
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
Randi B Gombos, Ana Gonzalez, +24 authors, Nicholas S Wilson.
PLoS One, 2018 Apr 05; 13(4). PMID: 29617360    Free PMC article.
Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.
Jeremy M Grenier, Stephen T Yeung, Kamal M Khanna.
Front Immunol, 2018 Apr 07; 9. PMID: 29623082    Free PMC article.
Novel Systemic Therapies for Advanced Gastric Cancer.
Hong Jun Kim, Sang Cheul Oh.
J Gastric Cancer, 2018 Apr 10; 18(1). PMID: 29629216    Free PMC article.
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
Roberta Zappasodi, Taha Merghoub, Jedd D Wolchok.
Cancer Cell, 2018 Apr 11; 33(4). PMID: 29634946    Free PMC article.
Highly Cited. Review.
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima.
Front Oncol, 2018 Apr 13; 8. PMID: 29644214    Free PMC article.
Highly Cited. Review.
Therapeutic Potential of Thymoquinone in Glioblastoma Treatment: Targeting Major Gliomagenesis Signaling Pathways.
Fabliha Ahmed Chowdhury, Md Kamal Hossain, +2 authors, Muhammad Shahdaat Bin Sayeed.
Biomed Res Int, 2018 Apr 14; 2018. PMID: 29651429    Free PMC article.
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.
Matthew D Hellmann, Tavi Nathanson, +29 authors, Jedd D Wolchok.
Cancer Cell, 2018 Apr 17; 33(5). PMID: 29657128    Free PMC article.
Highly Cited.
TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
Heng-Jia Liu, Patrick H Lizotte, +8 authors, Elizabeth P Henske.
JCI Insight, 2018 Apr 20; 3(8). PMID: 29669930    Free PMC article.
A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer.
Cesar August Santa-Maria, Taigo Kato, +14 authors, Francis J Giles.
Oncotarget, 2018 May 04; 9(27). PMID: 29721177    Free PMC article.
Modeling combination therapy for breast cancer with BET and immune checkpoint inhibitors.
Xiulan Lai, Andrew Stiff, +3 authors, Avner Friedman.
Proc Natl Acad Sci U S A, 2018 May 08; 115(21). PMID: 29735668    Free PMC article.
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
Young Kwang Chae, Ayush Arya, +4 authors, Francis Giles.
J Immunother Cancer, 2018 May 18; 6(1). PMID: 29769148    Free PMC article.
Highly Cited. Review.
Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion.
Flávia Castro, Ana Patrícia Cardoso, +2 authors, Maria José Oliveira.
Front Immunol, 2018 May 22; 9. PMID: 29780381    Free PMC article.
Highly Cited. Review.
In Situ Vaccination with Cowpea vs Tobacco Mosaic Virus against Melanoma.
Abner A Murray, Chao Wang, Steven Fiering, Nicole F Steinmetz.
Mol Pharm, 2018 May 26; 15(9). PMID: 29798673    Free PMC article.
Bacillus Calmette-Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer.
Yonghua Wang, Jing Liu, +6 authors, Haitao Niu.
Onco Targets Ther, 2018 May 31; 11. PMID: 29844686    Free PMC article.
Immunotherapeutic interventions of Triple Negative Breast Cancer.
Zehuan Li, Yiran Qiu, +2 authors, Jin Wang.
J Transl Med, 2018 Jun 01; 16(1). PMID: 29848327    Free PMC article.
Molecular and clinical characterization of IDH associated immune signature in lower-grade gliomas.
Zenghui Qian, Yiming Li, +4 authors, Xing Liu.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872572    Free PMC article.
Phosphoinositide 3-kinase δ inhibition promotes antitumor responses but antagonizes checkpoint inhibitors.
Ee Lyn Lim, Fiorella M Cugliandolo, +3 authors, Klaus Okkenhaug.
JCI Insight, 2018 Jun 08; 3(11). PMID: 29875319    Free PMC article.
B7-H4 Modulates Regulatory CD4+ T Cell Induction and Function via Ligation of a Semaphorin 3a/Plexin A4/Neuropilin-1 Complex.
Joseph R Podojil, Ming-Yi Chiang, +10 authors, Stephen D Miller.
J Immunol, 2018 Jun 15; 201(3). PMID: 29898965    Free PMC article.
Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma.
Alyona Weinstein, Ruth-Ann Gordon, +7 authors, Karla Lingard.
J Adv Pract Oncol, 2017 Jan 01; 8(1). PMID: 29900017    Free PMC article.
LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade.
Wanqiang Sheng, Martin W LaFleur, +13 authors, Yang Shi.
Cell, 2018 Jun 26; 174(3). PMID: 29937226    Free PMC article.
Highly Cited.
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.
Jean-David Fumet, Nicolas Isambert, +6 authors, Francois Ghiringhelli.
ESMO Open, 2018 Jun 27; 3(4). PMID: 29942666    Free PMC article.
PD-L1, TIM-3, and CTLA-4 Blockade Fails To Promote Resistance to Secondary Infection with Virulent Strains of Toxoplasma gondii.
Samantha D Splitt, Scott P Souza, +4 authors, Kirk D C Jensen.
Infect Immun, 2018 Jul 04; 86(9). PMID: 29967089    Free PMC article.
B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses.
Renata Ariza Marques Rossetti, Noely Paula Cristina Lorenzi, +7 authors, Ana Paula Lepique.
PLoS One, 2018 Jul 06; 13(7). PMID: 29975708    Free PMC article.
Perspectives of Immune Suppression in the Tumor Microenvironment Promoting Oral Malignancy.
Nobuo Kondoh, Masako Mizuno-Kamiya, +5 authors, Iwai Tohnai.
Open Dent J, 2018 Jul 11; 12. PMID: 29988281    Free PMC article.
Novel tumour antigens and the development of optimal vaccine design.
Victoria A Brentville, Suha Atabani, Katherine Cook, Lindy G Durrant.
Ther Adv Vaccines Immunother, 2018 Jul 13; 6(2). PMID: 29998219    Free PMC article.
Autoantigen-Harboring Apoptotic Cells Hijack the Coinhibitory Pathway of T Cell Activation.
Abraam M Yakoub, Ralph Schulz, Martina Seiffert, Mark Sadek.
Sci Rep, 2018 Jul 14; 8(1). PMID: 30002409    Free PMC article.
Regorafenib in hepatocellular carcinoma: latest evidence and clinical implications.
Nicola Personeni, Tiziana Pressiani, Armando Santoro, Lorenza Rimassa.
Drugs Context, 2018 Jul 14; 7. PMID: 30002715    Free PMC article.
Update on systemic therapy for advanced cutaneous melanoma and recent development of novel drugs.
Thein Swe, Kevin B Kim.
Clin Exp Metastasis, 2018 Jul 19; 35(5-6). PMID: 30019239
Efficacy and immune activation of ipilimumab in early-stage lung cancer patients.
Shingo Noguchi, Kazuhiro Yatera.
J Thorac Dis, 2018 Jul 20; 10(Suppl 17). PMID: 30023087    Free PMC article.
The evolving immunotherapeutic landscape in advanced oesophagogastric cancer.
Michael Flynn, Kate Young, David Cunningham, Naureen Starling.
Ther Adv Med Oncol, 2018 Jul 24; 10. PMID: 30034550    Free PMC article.
Cancer Stem Cell Vaccination With PD-L1 and CTLA-4 Blockades Enhances the Eradication of Melanoma Stem Cells in a Mouse Tumor Model.
Fang Zheng, Jianzhong Dang, +7 authors, Qiao Li.
J Immunother, 2018 Aug 01; 41(8). PMID: 30063587    Free PMC article.
OX40 Stimulation Enhances Protective Immune Responses Induced After Vaccination With Attenuated Malaria Parasites.
Ahmad Syibli Othman, Blandine M Franke-Fayard, +9 authors, Shahid M Khan.
Front Cell Infect Microbiol, 2018 Aug 04; 8. PMID: 30073152    Free PMC article.
Next Generation Cancer Vaccines-Make It Personal!
Angelika Terbuch, Juanita Lopez.
Vaccines (Basel), 2018 Aug 12; 6(3). PMID: 30096953    Free PMC article.
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo.
Sarwish Rafiq, Oladapo O Yeku, +14 authors, Renier J Brentjens.
Nat Biotechnol, 2018 Aug 14; 36(9). PMID: 30102295    Free PMC article.
Highly Cited.
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Yelena Y Janjigian, Johanna Bendell, +13 authors, Dung T Le.
J Clin Oncol, 2018 Aug 16; 36(28). PMID: 30110194    Free PMC article.
Highly Cited.
Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.
Jong-Ho Cha, Wen-Hao Yang, +25 authors, Mien-Chie Hung.
Mol Cell, 2018 Aug 18; 71(4). PMID: 30118680    Free PMC article.
Highly Cited.
Several Follicular Regulatory T Cell Subsets With Distinct Phenotype and Function Emerge During Germinal Center Reactions.
Nicolas Fazilleau, Meryem Aloulou.
Front Immunol, 2018 Aug 29; 9. PMID: 30150980    Free PMC article.
Insights Into the Molecular Mechanisms of T Follicular Helper-Mediated Immunity and Pathology.
Lei Qin, Tayab C Waseem, +4 authors, Roza Nurieva.
Front Immunol, 2018 Aug 31; 9. PMID: 30158933    Free PMC article.
A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity.
Prabhakaran Kumar, Palash Bhattacharya, Bellur S Prabhakar.
J Autoimmun, 2018 Sep 04; 95. PMID: 30174217    Free PMC article.
Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy.
Priyamvada Jayaprakash, Midan Ai, +15 authors, Michael A Curran.
J Clin Invest, 2018 Sep 07; 128(11). PMID: 30188869    Free PMC article.
Highly Cited.
Combination therapies in advanced melanoma.
Paolo A Ascierto.
Melanoma Manag, 2014 Aug 01; 1(1). PMID: 30190810    Free PMC article.
Ipilimumab for the treatment of melanoma.
Shikha Jain, Joseph I Clark.
Melanoma Manag, 2015 Feb 01; 2(1). PMID: 30190829    Free PMC article.
Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma.
Ester Simeone, Antonio M Grimaldi, Paolo A Ascierto.
Melanoma Manag, 2015 Feb 01; 2(1). PMID: 30190830    Free PMC article.
Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Shouheng Lin, Guohua Huang, +23 authors, Peng Li.
MAbs, 2018 Sep 12; 10(8). PMID: 30204048    Free PMC article.
RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade.
Shanthi Ganesh, Xue Shui, +4 authors, Marc T Abrams.
Mol Ther, 2018 Oct 03; 26(11). PMID: 30274786    Free PMC article.
Ibuprofen supports macrophage differentiation, T cell recruitment, and tumor suppression in a model of postpartum breast cancer.
Nathan D Pennock, Holly A Martinson, +6 authors, Pepper Schedin.
J Immunother Cancer, 2018 Oct 05; 6(1). PMID: 30285905    Free PMC article.
Protein-based nanoparticles in cancer vaccine development.
Medea Neek, Tae Il Kim, Szu-Wen Wang.
Nanomedicine, 2018 Oct 07; 15(1). PMID: 30291897    Free PMC article.
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity.
David A Knorr, Rony Dahan, Jeffrey V Ravetch.
Proc Natl Acad Sci U S A, 2018 Oct 10; 115(43). PMID: 30297432    Free PMC article.
Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against P815 mastocytoma.
Alessandra Lopes, Kevin Vanvarenberg, +5 authors, Gaëlle Vandermeulen.
Sci Rep, 2018 Oct 26; 8(1). PMID: 30356111    Free PMC article.
Mathematical modeling identifies Lck as a potential mediator for PD-1 induced inhibition of early TCR signaling.
Theinmozhi Arulraj, Debashis Barik.
PLoS One, 2018 Oct 26; 13(10). PMID: 30356330    Free PMC article.
Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining.
Sarah Péricart, Marie Tosolini, +10 authors, Camille Laurent.
Cancers (Basel), 2018 Nov 06; 10(11). PMID: 30384489    Free PMC article.
Targeting Chemokines and Chemokine Receptors in Melanoma and Other Cancers.
Nicolas Jacquelot, Connie P M Duong, Gabrielle T Belz, Laurence Zitvogel.
Front Immunol, 2018 Nov 14; 9. PMID: 30420855    Free PMC article.
The efficacy and safety of immune checkpoint inhibitor combination therapy in lung cancer: a systematic review and meta-analysis.
Min Peng, Xing Li, +3 authors, Qi Bin Song.
Onco Targets Ther, 2018 Nov 15; 11. PMID: 30425525    Free PMC article.
Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results.
Jacek Mackiewicz, Tomasz Burzykowski, Dariusz Iżycki, Andrzej Mackiewicz.
J Immunother Cancer, 2018 Nov 30; 6(1). PMID: 30486884    Free PMC article.
Expression of the immune checkpoint receptor TIGIT in Hodgkin's lymphoma.
Wenchao Li, Niclas C Blessin, +24 authors, Andrea Hinsch.
BMC Cancer, 2018 Dec 06; 18(1). PMID: 30514251    Free PMC article.
Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
Iris Koske, Annika Rössler, +7 authors, Dorothee von Laer.
Int J Cancer, 2019 Apr 12; 145(7). PMID: 30972741    Free PMC article.
Hyperglycemia-Induced Aberrant Cell Proliferation; A Metabolic Challenge Mediated by Protein O-GlcNAc Modification.
Tamás Nagy, Viktória Fisi, +3 authors, Attila Miseta.
Cells, 2019 Aug 31; 8(9). PMID: 31466420    Free PMC article.
Complex interactions between the microbiome and cancer immune therapy.
Drew J Schwartz, Olivia N Rebeck, Gautam Dantas.
Crit Rev Clin Lab Sci, 2019 Sep 19; 56(8). PMID: 31526274    Free PMC article.
Dual targeting of RANKL and PD-1 with a bispecific antibody improves anti-tumor immunity.
William C Dougall, Amelia Roman Aguilera, Mark J Smyth.
Clin Transl Immunology, 2019 Oct 02; 8(10). PMID: 31572609    Free PMC article.
Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
Spencer C Wei, Nana-Ama A S Anang, +8 authors, James P Allison.
Proc Natl Acad Sci U S A, 2019 Oct 23; 116(45). PMID: 31636208    Free PMC article.
From fiction to science: clinical potentials and regulatory considerations of gene editing.
Maria Schacker, Diane Seimetz.
Clin Transl Med, 2019 Oct 23; 8(1). PMID: 31637541    Free PMC article.
Targeting CXCR4 potentiates anti-PD-1 efficacy modifying the tumor microenvironment and inhibiting neoplastic PD-1.
Crescenzo D'Alterio, Maria Buoncervello, +16 authors, Stefania Scala.
J Exp Clin Cancer Res, 2019 Oct 30; 38(1). PMID: 31661001    Free PMC article.
T Regulatory Cells and Priming the Suppressive Tumor Microenvironment.
Christina M Paluskievicz, Xuefang Cao, +3 authors, Jonathan S Bromberg.
Front Immunol, 2019 Nov 05; 10. PMID: 31681327    Free PMC article.
Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies.
José Medina-Echeverz, Maria Hinterberger, +11 authors, Henning Lauterbach.
Nat Commun, 2019 Nov 07; 10(1). PMID: 31695037    Free PMC article.
Lithraea caustic (Litre) Extract Promotes an Antitumor Response Against B16 Melanoma.
Claudia Robles-Planells, Sofia A Michelson, +15 authors, Claudio Acuña-Castillo.
Front Pharmacol, 2019 Nov 07; 10. PMID: 31695610    Free PMC article.
Perspectives on Recent Progress in Focused Ultrasound Immunotherapy.
Natasha D Sheybani, Richard J Price.
Theranostics, 2019 Nov 07; 9(25). PMID: 31695798    Free PMC article.
An Engineered AAV6-Based Vaccine Induces High Cytolytic Anti-Tumor Activity by Directly Targeting DCs and Improves Ag Presentation.
Karina Krotova, Andrew Day, George Aslanidi.
Mol Ther Oncolytics, 2019 Nov 14; 15. PMID: 31720373    Free PMC article.
Expression and clinical significance of PD‑1 in hepatocellular carcinoma tissues detected by a novel mouse anti-human PD‑1 monoclonal antibody.
Ziwei Li, Bin Li, +6 authors, Jianhong Chen.
Int J Oncol, 2018 Apr 06; 52(6). PMID: 29620156    Free PMC article.
Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
Lindsey M Kuehm, Kyle Wolf, +2 authors, Ryan M Teague.
Cancer Immunol Immunother, 2019 May 20; 68(7). PMID: 31104075    Free PMC article.
Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer.
Cindy Mendes, Jacinta Serpa.
Antioxidants (Basel), 2019 Dec 05; 8(12). PMID: 31795465    Free PMC article.
Differential Expression of Immune Checkpoint Molecules on CD8+ T Cells Specific for Immunodominant and Subdominant Herpes Simplex Virus 1 Epitopes.
Kate L Carroll, Lyndsay Avery, +4 authors, Anthony J St Leger.
J Virol, 2019 Oct 28; 94(2). PMID: 31645447    Free PMC article.
Therapeutic melanoma vaccine with cancer stem cell phenotype represses exhaustion and maintains antigen-specific T cell stemness by up-regulating BCL6.
Patrycja Czerwinska, Marcin Rucinski, +6 authors, Andrzej Mackiewicz.
Oncoimmunology, 2020 Feb 01; 9(1). PMID: 32002306    Free PMC article.
Mesenchymal stem cells derived from iPSCs expressing interleukin-24 inhibit the growth of melanoma in the tumor-bearing mouse model.
Zheng Wu, Wei Liu, +12 authors, Desheng Liang.
Cancer Cell Int, 2020 Feb 06; 20. PMID: 32015693    Free PMC article.
Yap suppresses T-cell function and infiltration in the tumor microenvironment.
Eleni Stampouloglou, Nan Cheng, +4 authors, Xaralabos Varelas.
PLoS Biol, 2020 Jan 14; 18(1). PMID: 31929526    Free PMC article.
Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Gayathri Vijayakumar, Stephen McCroskery, Peter Palese.
J Virol, 2019 Nov 07; 94(3). PMID: 31694938    Free PMC article.
Built-In Active Microneedle Patch with Enhanced Autonomous Drug Delivery.
Miguel Angel Lopez-Ramirez, Fernando Soto, +10 authors, Joseph Wang.
Adv Mater, 2019 Nov 05; 32(1). PMID: 31682039    Free PMC article.
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies.
Hongxing Shen, Eddy Shih-Hsin Yang, +4 authors, Lewis Zhichang Shi.
Genes Dis, 2020 Feb 12; 6(3). PMID: 32042863    Free PMC article.
Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms.
Mikayel Mkrtichyan, Yana G Najjar, +5 authors, Samir N Khleif.
Eur J Immunol, 2011 Jun 29; 41(10). PMID: 21710477    Free PMC article.
B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets.
Mikayel Mkrtichyan, Yana G Najjar, +5 authors, Samir N Khleif.
J Immunol, 2012 Jul 28; 189(5). PMID: 22837483    Free PMC article.
VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study.
Elizabeth Smyth, Maren Knödler, +6 authors, Florian Lordick.
Front Oncol, 2020 Feb 23; 9. PMID: 32083013    Free PMC article.
Survival analysis of immune-related lncRNA in low-grade glioma.
Xiaozhi Li, Yutong Meng.
BMC Cancer, 2019 Aug 20; 19(1). PMID: 31419958    Free PMC article.
Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy.
Guojun Chen, Zhitong Chen, +6 authors, Zhen Gu.
Proc Natl Acad Sci U S A, 2020 Feb 08; 117(7). PMID: 32029590    Free PMC article.
NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing.
Isabel Prager, Clarissa Liesche, +9 authors, Carsten Watzl.
J Exp Med, 2019 Jul 05; 216(9). PMID: 31270246    Free PMC article.
Highly Cited.
Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response.
Qingyang Xiao, André Nobre, +5 authors, Isabel Barragán.
J Clin Med, 2020 Jan 24; 9(1). PMID: 31968651    Free PMC article.
Comparative Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Advanced Cancer: A Systematic Review and Meta-Analysis.
Yi Yang, Gang Jin, +7 authors, Zijiang Zhu.
Front Pharmacol, 2020 Mar 03; 11. PMID: 32116716    Free PMC article.
Systematic Review.
Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment.
Sara Saab, Hussein Zalzale, +3 authors, Humam Kadara.
Front Immunol, 2020 Mar 03; 11. PMID: 32117295    Free PMC article.
TLR1/2 ligand enhances antitumor efficacy of CTLA-4 blockade by increasing intratumoral Treg depletion.
Naveen Sharma, Jean Vacher, James P Allison.
Proc Natl Acad Sci U S A, 2019 May 12; 116(21). PMID: 31076558    Free PMC article.
A QSP Model for Predicting Clinical Responses to Monotherapy, Combination and Sequential Therapy Following CTLA-4, PD-1, and PD-L1 Checkpoint Blockade.
Oleg Milberg, Chang Gong, +6 authors, Aleksander S Popel.
Sci Rep, 2019 Aug 04; 9(1). PMID: 31375756    Free PMC article.
Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma.
Soudabeh Rad Pour, Hiromasa Morikawa, +11 authors, Jesper Tegnér.
Sci Rep, 2019 Aug 23; 9(1). PMID: 31434983    Free PMC article.
Preclinical mouse solid tumour models: status quo, challenges and perspectives.
Nicolas Gengenbacher, Mahak Singhal, Hellmut G Augustin.
Nat Rev Cancer, 2017 Oct 28; 17(12). PMID: 29077691
Highly Cited. Review.
YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity.
Xuhao Ni, Jinhui Tao, +17 authors, Fan Pan.
Cancer Discov, 2018 Jun 17; 8(8). PMID: 29907586    Free PMC article.
Highly Cited.
Therapeutic cancer vaccine: building the future from lessons of the past.
T Tran, C Blanc, +3 authors, Eric Tartour.
Semin Immunopathol, 2018 Jul 07; 41(1). PMID: 29978248
Sensitizing the Tumor Microenvironment to Immune Checkpoint Therapy.
Rachael M Zemek, Wee Loong Chin, +3 authors, W Joost Lesterhuis.
Front Immunol, 2020 Mar 07; 11. PMID: 32133005    Free PMC article.
Mucosal HPV E6/E7 Peptide Vaccination in Combination with Immune Checkpoint Modulation Induces Regression of HPV+ Oral Cancers.
Stephanie Dorta-Estremera, Renee L Chin, +7 authors, K Jagannadha Sastry.
Cancer Res, 2018 Jul 29; 78(18). PMID: 30054333    Free PMC article.
The Current and Evolving Landscape of First-Line Treatments for Advanced Renal Cell Carcinoma.
Emiliano Calvo, Camillio Porta, Viktor Grünwald, Bernard Escudier.
Oncologist, 2018 Aug 31; 24(3). PMID: 30158285    Free PMC article.
Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade.
John Lynes, Sadhana Jackson, +19 authors, Edjah K Nduom.
Neurosurgery, 2018 Sep 07; 84(4). PMID: 30189044    Free PMC article.
Dietary Protein Restriction Reprograms Tumor-Associated Macrophages and Enhances Immunotherapy.
Ashley Orillion, Nur P Damayanti, +13 authors, Roberto Pili.
Clin Cancer Res, 2018 Sep 08; 24(24). PMID: 30190370    Free PMC article.
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Lillian L Siu, Caroline Even, +18 authors, Jérôme Fayette.
JAMA Oncol, 2018 Nov 02; 5(2). PMID: 30383184    Free PMC article.
Highly Cited.
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.
Livnat Jerby-Arnon, Parin Shah, +49 authors, Aviv Regev.
Cell, 2018 Nov 06; 175(4). PMID: 30388455    Free PMC article.
Highly Cited.
Tumor-conditional anti-CTLA4 uncouples antitumor efficacy from immunotherapy-related toxicity.
Chien-Chun Steven Pai, Donald M Simons, +22 authors, Lawrence Fong.
J Clin Invest, 2018 Dec 12; 129(1). PMID: 30530991    Free PMC article.
Mechanisms and Functions of Chemerin in Cancer: Potential Roles in Therapeutic Intervention.
Woo Jae Shin, Brian A Zabel, Russell K Pachynski.
Front Immunol, 2018 Dec 18; 9. PMID: 30555465    Free PMC article.
Systematic Review.
Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.
Can Liu, Hua He, +2 authors, Yanguang Cao.
Br J Cancer, 2018 Dec 28; 120(3). PMID: 30587849    Free PMC article.
Antigen delivery targeted to tumor-associated macrophages overcomes tumor immune resistance.
Daisuke Muraoka, Naohiro Seo, +17 authors, Hiroshi Shiku.
J Clin Invest, 2019 Jan 11; 129(3). PMID: 30628894    Free PMC article.
Loss of E-Cadherin Inhibits CD103 Antitumor Activity and Reduces Checkpoint Blockade Responsiveness in Melanoma.
Bradley D Shields, Brian Koss, +8 authors, Alan J Tackett.
Cancer Res, 2019 Jan 25; 79(6). PMID: 30674537    Free PMC article.
Immune Exhaustion: Past Lessons and New Insights from Lymphocytic Choriomeningitis Virus.
Shannon M Kahan, Allan J Zajac.
Viruses, 2019 Feb 20; 11(2). PMID: 30781904    Free PMC article.
α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas.
E Dodagatta-Marri, D S Meyer, +21 authors, R J Akhurst.
J Immunother Cancer, 2019 Mar 06; 7(1). PMID: 30832732    Free PMC article.
Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Abhishek S Kashyap, Tamara Thelemann, +8 authors, Alfred Zippelius.
J Immunother Cancer, 2019 Mar 16; 7(1). PMID: 30871609    Free PMC article.
HIF-1α Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma.
Jason Miska, Catalina Lee-Chang, +10 authors, Maciej S Lesniak.
Cell Rep, 2019 Apr 04; 27(1). PMID: 30943404    Free PMC article.
Highly Cited.
Assessing Therapeutic Efficacy in Real-time by Hyperpolarized Magnetic Resonance Metabolic Imaging.
Prasanta Dutta, Travis C Salzillo, +8 authors, Pratip K Bhattacharya.
Cells, 2019 Apr 14; 8(4). PMID: 30978984    Free PMC article.
Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies.
Dongxu Wang, Jianzhen Lin, +7 authors, Haitao Zhao.
J Hematol Oncol, 2019 Apr 25; 12(1). PMID: 31014381    Free PMC article.
Emerging therapies for small cell lung cancer.
Sen Yang, Zhe Zhang, Qiming Wang.
J Hematol Oncol, 2019 May 03; 12(1). PMID: 31046803    Free PMC article.
Highly Cited. Review.
Injectable polypeptide hydrogel-based co-delivery of vaccine and immune checkpoint inhibitors improves tumor immunotherapy.
Huijuan Song, Pengxiang Yang, +3 authors, Weiwei Wang.
Theranostics, 2019 Jun 01; 9(8). PMID: 31149045    Free PMC article.
Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma.
Spela Kos, Alessandra Lopes, +6 authors, Gaelle Vandermeulen.
PLoS One, 2019 Jun 01; 14(5). PMID: 31150505    Free PMC article.
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance.
Xiaoguang Li, Zhida Liu, +8 authors, Yang-Xin Fu.
Nat Commun, 2019 Jul 22; 10(1). PMID: 31324798    Free PMC article.
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors.
Danny N Khalil, Nathan Suek, +18 authors, Taha Merghoub.
J Clin Invest, 2019 Jul 23; 129(8). PMID: 31329159    Free PMC article.
Macrophage-Mediated Subversion of Anti-Tumour Immunity.
Valeria Quaranta, Michael C Schmid.
Cells, 2019 Jul 25; 8(7). PMID: 31331034    Free PMC article.
Neoantigen vaccine: an emerging tumor immunotherapy.
Miao Peng, Yongzhen Mo, +10 authors, Zhaoyang Zeng.
Mol Cancer, 2019 Aug 25; 18(1). PMID: 31443694    Free PMC article.
Highly Cited. Review.
Activation of 4-1BB on Liver Myeloid Cells Triggers Hepatitis via an Interleukin-27-Dependent Pathway.
Todd Bartkowiak, Ashvin R Jaiswal, +8 authors, Michael A Curran.
Clin Cancer Res, 2018 Jan 06; 24(5). PMID: 29301830    Free PMC article.
Anti-PD-1 and Novel Combinations in the Treatment of Melanoma-An Update.
Frank Friedrich Gellrich, Marc Schmitz, Stefan Beissert, Friedegund Meier.
J Clin Med, 2020 Jan 18; 9(1). PMID: 31947592    Free PMC article.
Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies.
Sonam Puri, Michael Shafique.
Drugs Context, 2020 Mar 12; 9. PMID: 32158484    Free PMC article.
Adjuvant Screen Identifies Synthetic DNA-Encoding Flt3L and CD80 Immunotherapeutics as Candidates for Enhancing Anti-tumor T Cell Responses.
Amy Haseley Thorne, Kirsten N Malo, +8 authors, Laurent Humeau.
Front Immunol, 2020 Mar 13; 11. PMID: 32161596    Free PMC article.
Oncolytic Virus Encoding a Master Pro-Inflammatory Cytokine Interleukin 12 in Cancer Immunotherapy.
Hong-My Nguyen, Kirsten Guz-Montgomery, Dipongkor Saha.
Cells, 2020 Feb 14; 9(2). PMID: 32050597    Free PMC article.
Supportive roles of brain macrophages in CNS metastases and assessment of new approaches targeting their functions.
Hua You, Szymon Baluszek, Bozena Kaminska.
Theranostics, 2020 Mar 21; 10(7). PMID: 32194848    Free PMC article.
Novel calreticulin-nanoparticle in combination with focused ultrasound induces immunogenic cell death in melanoma to enhance antitumor immunity.
Sri Nandhini Sethuraman, Mohit Pratap Singh, +6 authors, Ashish Ranjan.
Theranostics, 2020 Mar 25; 10(8). PMID: 32206098    Free PMC article.
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers.
Neal Ready, Matthew D Hellmann, +25 authors, Suresh S Ramalingam.
J Clin Oncol, 2019 Feb 21; 37(12). PMID: 30785829    Free PMC article.
Highly Cited.
Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy.
Afsheen Raza, Maysaloun Merhi, +4 authors, Said Dermime.
J Transl Med, 2020 Mar 30; 18(1). PMID: 32220256    Free PMC article.
Low-Dose Total Body Irradiation Can Enhance Systemic Immune Related Response Induced by Hypo-Fractionated Radiation.
Jing Liu, Jie Zhou, +10 authors, JingBo Wu.
Front Immunol, 2019 Mar 16; 10. PMID: 30873170    Free PMC article.
Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma.
Duaa O Khair, Heather J Bax, +22 authors, Sophia N Karagiannis.
Front Immunol, 2019 Apr 04; 10. PMID: 30941125    Free PMC article.
Highly Cited. Review.
Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients.
Prajakta Shinde, Sameer Melinkeri, +2 authors, Lalita Limaye.
Front Immunol, 2019 Jun 06; 10. PMID: 31164886    Free PMC article.
Immune microenvironment modulation unmasks therapeutic benefit of radiotherapy and checkpoint inhibition.
Jared M Newton, Aurelie Hanoteau, +11 authors, Andrew G Sikora.
J Immunother Cancer, 2019 Aug 15; 7(1). PMID: 31409394    Free PMC article.
Inhibition of Hedgehog signaling reprograms the dysfunctional immune microenvironment in breast cancer.
Ann Hanna, Brandon J Metge, +5 authors, Lalita A Shevde.
Oncoimmunology, 2019 Feb 07; 8(3). PMID: 30723576    Free PMC article.
T Cell Dysfunction in Cancer Immunity and Immunotherapy.
Anliang Xia, Yan Zhang, +2 authors, Xiao-Jie Lu.
Front Immunol, 2019 Aug 06; 10. PMID: 31379886    Free PMC article.
Highly Cited. Review.
Deciphering the transcriptomic landscape of tumor-infiltrating CD8 lymphocytes in B16 melanoma tumors with single-cell RNA-Seq.
Santiago J Carmona, Imran Siddiqui, +2 authors, David Gfeller.
Oncoimmunology, 2020 Apr 22; 9(1). PMID: 32313720    Free PMC article.
Targeted Therapies Combined With Immune Checkpoint Therapy.
Peter A Prieto, Alexandre Reuben, Zachary A Cooper, Jennifer A Wargo.
Cancer J, 2016 Apr 26; 22(2). PMID: 27111910    Free PMC article.
Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges.
A Pavan, I Attili, +3 authors, L Bonanno.
J Immunother Cancer, 2019 Aug 07; 7(1). PMID: 31383005    Free PMC article.
Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
Dmitriy Zamarin, Robert A Burger, +11 authors, Carol Aghajanian.
J Clin Oncol, 2020 Apr 11; 38(16). PMID: 32275468    Free PMC article.
Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.
Muhammad Zaeem Noman, Santiago Parpal, +10 authors, Bassam Janji.
Sci Adv, 2020 Jun 05; 6(18). PMID: 32494661    Free PMC article.
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Joseph Tintelnot, Eray Goekkurt, +14 authors, Alexander Stein.
BMC Cancer, 2020 Jun 04; 20(1). PMID: 32487035    Free PMC article.
Identification of immune-related biomarkers associated with tumorigenesis and prognosis in cutaneous melanoma patients.
Biao Huang, Wei Han, Zu-Feng Sheng, Guo-Liang Shen.
Cancer Cell Int, 2020 Jun 09; 20. PMID: 32508531    Free PMC article.
Dendritic Cells and Their Role in Immunotherapy.
Alycia Gardner, Álvaro de Mingo Pulido, Brian Ruffell.
Front Immunol, 2020 Jun 09; 11. PMID: 32508825    Free PMC article.
TAK1 regulates the tumor microenvironment through inflammatory, angiogenetic and apoptotic signaling cascades.
Scott A Scarneo, Kelly W Yang, +4 authors, Timothy A J Haystead.
Oncotarget, 2020 Jun 12; 11(21). PMID: 32523651    Free PMC article.
Adoptive cell therapy in combination with checkpoint inhibitors in ovarian cancer.
Anders Handrup Kverneland, Magnus Pedersen, +11 authors, Inge Marie Svane.
Oncotarget, 2020 Jun 18; 11(22). PMID: 32547707    Free PMC article.
Effect of Different Expression of Immune-Related lncRNA on Colon Adenocarcinoma and Its Relation to Prognosis.
Meiwei Mu, Yi Tang, +4 authors, Qisheng Su.
Biomed Res Int, 2020 Jul 01; 2020. PMID: 32596355    Free PMC article.
Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas.
Qing Zhang, Fusheng Liu.
Cell Death Dis, 2020 Jun 27; 11(6). PMID: 32587256    Free PMC article.
A Tale of Immune-Related Adverse Events With Sequential Trials of Checkpoint Inhibitors in a Patient With Metastatic Renal Cell Carcinoma.
Vinit Singh, Yvonne Chu, Varsha Gupta, Charlie Weige Zhao.
Cureus, 2020 Jul 09; 12(6). PMID: 32637277    Free PMC article.
Nanoscale Metal-Organic Framework Mediates Radical Therapy to Enhance Cancer Immunotherapy.
Kaiyuan Ni, Theint Aung, +3 authors, Wenbin Lin.
Chem, 2019 Aug 07; 5(7). PMID: 31384694    Free PMC article.
Tumors induce de novo steroid biosynthesis in T cells to evade immunity.
Bidesh Mahata, Jhuma Pramanik, +14 authors, Sarah A Teichmann.
Nat Commun, 2020 Jul 19; 11(1). PMID: 32680985    Free PMC article.
A heat-shocked melanoma cell lysate vaccine enhances tumor infiltration by prototypic effector T cells inhibiting tumor growth.
María Alejandra Gleisner, Cristián Pereda, +9 authors, Flavio Salazar-Onfray.
J Immunother Cancer, 2020 Jul 22; 8(2). PMID: 32690772    Free PMC article.
BRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cells.
Patryk Górniak, Maja Wasylecka-Juszczyńska, +4 authors, Przemysław Juszczyński.
Mol Oncol, 2020 Apr 25; 14(8). PMID: 32330348    Free PMC article.
Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy.
Adrienne M Luoma, Shengbao Suo, +13 authors, Kai W Wucherpfennig.
Cell, 2020 Jul 01; 182(3). PMID: 32603654    Free PMC article.
Immune checkpoint targeting TIGIT in hepatocellular carcinoma.
Qiuxian Zheng, Jia Xu, +6 authors, Zhi Chen.
Am J Transl Res, 2020 Aug 11; 12(7). PMID: 32774695    Free PMC article.
Necroptotic-susceptible dendritic cells exhibit enhanced antitumor activities in mice.
Zhanran Zhao, Guangzhi Zhang, Yuefang Sun, Astar Winoto.
Immun Inflamm Dis, 2020 Jul 15; 8(3). PMID: 32663380    Free PMC article.
An Immunophenotyping of Ovarian Cancer With Clinical and Immunological Significance.
Kai Yang, Weiwei Zhao, +7 authors, Kang Li.
Front Immunol, 2018 Apr 10; 9. PMID: 32793247    Free PMC article.
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma.
Stefan K Barta, Jasmine Zain, +14 authors, Yasuhiro Oki.
Clin Lymphoma Myeloma Leuk, 2019 Apr 29; 19(6). PMID: 31029646    Free PMC article.
Research Progress and Existing Problems for Abscopal Effect.
Di Wang, Xia Zhang, +6 authors, Jinming Yu.
Cancer Manag Res, 2020 Aug 18; 12. PMID: 32801902    Free PMC article.
Protective Activity of Programmed Cell Death Protein 1 Blockade and Synergy With Caspofungin in a Murine Invasive Pulmonary Aspergillosis Model.
Sebastian Wurster, Prema Robinson, +6 authors, Dimitrios P Kontoyiannis.
J Infect Dis, 2020 May 21; 222(6). PMID: 32432714    Free PMC article.
Scientifically based combination therapies with immuno-oncology checkpoint inhibitors.
Hui Yi Chew, Riccardo Dolcetti, Fiona Simpson.
Br J Clin Pharmacol, 2020 May 07; 86(9). PMID: 32372470    Free PMC article.
Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma.
Nethanel Asher, Guy Ben-Betzalel, +6 authors, Gal Markel.
Cancers (Basel), 2020 Aug 23; 12(8). PMID: 32824780    Free PMC article.
Epidermal activation of Hedgehog signaling establishes an immunosuppressive microenvironment in basal cell carcinoma by modulating skin immunity.
Sandra Grund-Gröschke, Daniela Ortner, +11 authors, Fritz Aberger.
Mol Oncol, 2020 Jul 03; 14(9). PMID: 32615027    Free PMC article.
Combinatorial approach to cancer immunotherapy: strength in numbers.
Anna E Vilgelm, Douglas B Johnson, Ann Richmond.
J Leukoc Biol, 2016 Jun 04; 100(2). PMID: 27256570    Free PMC article.
Rhesus Cytomegalovirus-Specific CD8+ Cytotoxic T Lymphocytes Do Not Become Functionally Exhausted in Chronic SIVmac239 Infection.
Brandon C Rosen, Nuria Pedreño-Lopez, +4 authors, David I Watkins.
Front Immunol, 2020 Sep 15; 11. PMID: 32922404    Free PMC article.
Generation of highly activated, antigen-specific tumor-infiltrating CD8+ T cells induced by a novel T cell-targeted immunotherapy.
Ava Vila-Leahey, Alecia MacKay, +3 authors, Marianne M Stanford.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923145    Free PMC article.
[First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer].
Xiaoxiao Peng, Qing Zhou.
Zhongguo Fei Ai Za Zhi, 2018 Dec 29; 21(12). PMID: 30591101    Free PMC article.
Biomarkers of immunotherapy in non-small cell lung cancer.
Lingling Wang, Yue Hu, +2 authors, Xiaochen Wang.
Oncol Lett, 2020 Sep 17; 20(5). PMID: 32934707    Free PMC article.
Metabolic reprograming of tumor-associated macrophages.
Abhishek Puthenveetil, Shweta Dubey.
Ann Transl Med, 2020 Sep 22; 8(16). PMID: 32953830    Free PMC article.
Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?
Purushottam Lamichhane, Neha P Amin, Manuj Agarwal, Narottam Lamichhane.
Medicines (Basel), 2018 Oct 27; 5(4). PMID: 30360504    Free PMC article.
Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
Silvia Martin Lluesma, Michele Graciotti, Cheryl Lai-Lai Chiang, Lana E Kandalaft.
Vaccines (Basel), 2018 Nov 28; 6(4). PMID: 30477198    Free PMC article.
Immunotherapy and Radiation - A New Combined Treatment Approach for Bladder Cancer?
Zachary S Buchwald, Jason A Efstathiou.
Bladder Cancer, 2015 Apr 30; 1(1). PMID: 30561443    Free PMC article.
Combination of immunogenic oncolytic adenovirus ONCOS-102 with anti-PD-1 pembrolizumab exhibits synergistic antitumor effect in humanized A2058 melanoma huNOG mouse model.
Lukasz Kuryk, Anne-Sophie W Møller, Magnus Jaderberg.
Oncoimmunology, 2019 Feb 05; 8(2). PMID: 30713786    Free PMC article.
Highly Cited.
Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy.
Sakshi Sahni, Gautam Valecha, Ankit Sahni.
Cureus, 2019 Feb 23; 10(12). PMID: 30788189    Free PMC article.
Macrophage Origin, Metabolic Reprogramming and IL-1 Signaling: Promises and Pitfalls in Lung Cancer.
Emma Guilbaud, Emmanuel L Gautier, Laurent Yvan-Charvet.
Cancers (Basel), 2019 Mar 06; 11(3). PMID: 30832375    Free PMC article.
Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System.
Shweta Joshi, Donald L Durden.
J Oncol, 2019 Mar 12; 2019. PMID: 30853982    Free PMC article.
Human Epididymis Secretory Protein 4 (HE4) Compromises Cytotoxic Mononuclear Cells via Inducing Dual Specificity Phosphatase 6.
Nicole E James, Matthew T Oliver, +9 authors, Ting C Zhao.
Front Pharmacol, 2019 Apr 04; 10. PMID: 30941033    Free PMC article.
The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer-Ways of Enhancing Immunotherapy Action.
Evangelos Koustas, Panagiotis Sarantis, +2 authors, Michalis V Karamouzis.
Cancers (Basel), 2019 Apr 25; 11(4). PMID: 31013961    Free PMC article.
Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations.
Ruth J Davis, Robert L Ferris, Nicole C Schmitt.
Cancers Head Neck, 2016 Oct 01; 1. PMID: 31093342    Free PMC article.
Multiple Myeloma: What Do We Do About Immunodeficiency?
Linrong Li, Liang Wang.
J Cancer, 2019 Jun 18; 10(7). PMID: 31205523    Free PMC article.
A Model for Apoptotic-Cell-Mediated Adaptive Immune Evasion via CD80-CTLA-4 Signaling.
Abraam M Yakoub, Stefan Schülke.
Front Pharmacol, 2019 Jun 20; 10. PMID: 31214024    Free PMC article.
PEG-Derivatized Dual-Functional Nanomicelles for Improved Cancer Therapy.
Yanping Li, Ting Zhang, Qinhui Liu, Jinhan He.
Front Pharmacol, 2019 Aug 06; 10. PMID: 31379579    Free PMC article.
A PD-L1-Based Cancer Vaccine Elicits Antitumor Immunity in a Mouse Melanoma Model.
Zhibing Lin, Yan Zhang, +4 authors, Rongxiu Li.
Mol Ther Oncolytics, 2019 Aug 07; 14. PMID: 31384666    Free PMC article.
Moderate physical exercise improves lymphocyte function in melanoma-bearing mice on a high-fat diet.
Cesar Miguel Momesso Dos Santos, Vinicius Leonardo Sousa Diniz, +13 authors, Renata Gorjão.
Nutr Metab (Lond), 2019 Sep 19; 16. PMID: 31528182    Free PMC article.
Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination? Natural Killer Cells in Vaccination.
Harold R Neely, Irina B Mazo, Carmen Gerlach, Ulrich H von Andrian.
Cold Spring Harb Perspect Biol, 2017 Dec 20; 10(10). PMID: 29254978    Free PMC article.
The Impact of Immune Cells on the Skeletal Muscle Microenvironment During Cancer Cachexia.
Brandon N VanderVeen, E Angela Murphy, James A Carson.
Front Physiol, 2020 Sep 29; 11. PMID: 32982782    Free PMC article.
Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma.
Ali Mehdi, Mikhael Attias, +5 authors, Shafaat Ahmed Rabbani.
Front Oncol, 2020 Sep 29; 10. PMID: 32983966    Free PMC article.
Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy.
Ji-Hae Kim, Young-Min Kim, +11 authors, Seung-Woo Lee.
Clin Transl Immunology, 2020 Oct 01; 9(9). PMID: 32994996    Free PMC article.
Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer.
Huabin Hu, Longjiang She, +7 authors, Jin Huang.
Front Oncol, 2020 Oct 06; 10. PMID: 33014826    Free PMC article.
The Diagnostic and Prognostic Value of a Liquid Biopsy for Esophageal Cancer: A Systematic Review and Meta-Analysis.
Daisuke Matsushita, Takaaki Arigami, +7 authors, Shoji Natsugoe.
Cancers (Basel), 2020 Oct 25; 12(10). PMID: 33096708    Free PMC article.
Regulatory T Cells in Cancer Immunotherapy: Basic Research Outcomes and Clinical Directions.
Guoming Zeng, Libo Jin, +9 authors, Da Sun.
Cancer Manag Res, 2020 Oct 30; 12. PMID: 33116895    Free PMC article.
Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model.
Pravin T P Kaumaya, Linlin Guo, +2 authors, Tanios Bekaii-Saab.
Oncoimmunology, 2020 Oct 30; 9(1). PMID: 33117602    Free PMC article.
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy.
Italia Falcone, Fabiana Conciatori, +4 authors, Michele Milella.
Cancers (Basel), 2020 Oct 11; 12(10). PMID: 33036192    Free PMC article.
Efficient Lymph Node-Targeted Delivery of Personalized Cancer Vaccines with Reactive Oxygen Species-Inducing Reduced Graphene Oxide Nanosheets.
Cheng Xu, Hao Hong, +6 authors, James J Moon.
ACS Nano, 2020 Sep 10; 14(10). PMID: 32902245    Free PMC article.
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic Phenotype.
Ashvin R Jaiswal, Arthur J Liu, +17 authors, Michael A Curran.
Cancer Immunol Res, 2020 Sep 13; 8(11). PMID: 32917656    Free PMC article.
Vaccine-induced CD8 T cells are redirected with peptide-MHC class I-IgG antibody fusion proteins to eliminate tumor cells in vivo.
Cornelia Fischer, Michael W Munks, +9 authors, Hendrik Knoetgen.
MAbs, 2020 Nov 06; 12(1). PMID: 33151105    Free PMC article.
Characterization of the Immune Cell Infiltration Landscape in Head and Neck Squamous Cell Carcinoma to Aid Immunotherapy.
Xinhai Zhang, Mengqi Shi, Tielou Chen, Boxin Zhang.
Mol Ther Nucleic Acids, 2020 Nov 25; 22. PMID: 33230435    Free PMC article.
Checkpoint immunotherapy in head and neck cancers.
Paul Zolkind, Ravindra Uppaluri.
Cancer Metastasis Rev, 2017 Aug 25; 36(3). PMID: 28836124    Free PMC article.
Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma.
Mackenzie E Malo, Kevin J H Allen, +3 authors, Ekaterina Dadachova.
Int J Mol Sci, 2020 Nov 22; 21(22). PMID: 33218169    Free PMC article.
Cellular constituents of immune escape within the tumor microenvironment.
Sid P Kerkar, Nicholas P Restifo.
Cancer Res, 2012 Jun 23; 72(13). PMID: 22721837    Free PMC article.
Highly Cited. Review.
Immunological insights from patients undergoing surgery on ipilimumab for metastatic melanoma.
David E Gyorki, Jianda Yuan, +8 authors, Charlotte E Ariyan.
Ann Surg Oncol, 2013 May 18; 20(9). PMID: 23681603    Free PMC article.
Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions.
Danielle M Lussier, Lauren O'Neill, +7 authors, Joseph N Blattman.
J Immunother, 2015 Mar 10; 38(3). PMID: 25751499    Free PMC article.
Highly Cited.
Emerging immunotherapies for bladder cancer.
Joseph W Kim, Yusuke Tomita, Jane Trepel, Andrea B Apolo.
Curr Opin Oncol, 2015 Mar 27; 27(3). PMID: 25811346    Free PMC article.
CTLA-4 methylation regulates the pathogenesis of myasthenia gravis and the expression of related cytokines.
Ti-Kun Fang, Cheng-Jun Yan, Juan Du.
Medicine (Baltimore), 2018 May 03; 97(18). PMID: 29718870    Free PMC article.
Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.
Emmett V Schmidt.
Semin Immunopathol, 2018 Oct 31; 41(1). PMID: 30374524    Free PMC article.
Therapeutic Targets for Bone and Soft-Tissue Sarcomas.
Shinji Miwa, Norio Yamamoto, +3 authors, Hiroyuki Tsuchiya.
Int J Mol Sci, 2019 Jan 10; 20(1). PMID: 30621224    Free PMC article.
Cancer research in the era of immunogenomics.
Yochai Wolf, Yardena Samuels.
ESMO Open, 2019 Jan 10; 3(7). PMID: 30622743    Free PMC article.
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
Margaret Ottaviano, Sabino De Placido, Paolo Antonio Ascierto.
Virchows Arch, 2019 Feb 13; 474(4). PMID: 30747264
Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan.
Satoru Senoo, Kiichiro Ninomiya, Katsuyuki Hotta, Katsuyuki Kiura.
Int J Clin Oncol, 2019 Mar 09; 24(5). PMID: 30847617
Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.
Toshiaki Takahashi, Akiko Tateishi, Andrey Bychkov, Junya Fukuoka.
Int J Mol Sci, 2019 May 28; 20(10). PMID: 31130676    Free PMC article.
Yeast-Derived β-Glucan in Cancer: Novel Uses of a Traditional Therapeutic.
Anne Geller, Rejeena Shrestha, Jun Yan.
Int J Mol Sci, 2019 Jul 28; 20(15). PMID: 31344853    Free PMC article.
Advances in engineering local drug delivery systems for cancer immunotherapy.
Peter Abdou, Zejun Wang, +4 authors, Zhen Gu.
Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2020 Apr 08; 12(5). PMID: 32255276    Free PMC article.
Manipulation of immune‒vascular crosstalk: new strategies towards cancer treatment.
Yang Zhao, Xiangrong Yu, Jia Li.
Acta Pharm Sin B, 2020 Dec 12; 10(11). PMID: 33304777    Free PMC article.
Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy.
Lydia S Lamb, Hao-Wen Sim, Ann I McCormack.
Front Endocrinol (Lausanne), 2020 Dec 15; 11. PMID: 33312158    Free PMC article.
Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Nityam Rathi, Taylor Ryan McFarland, +2 authors, Umang Swami.
Drugs, 2020 Dec 29; 81(2). PMID: 33369720    Free PMC article.
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE).
Rana R McKay, Bradley A McGregor, +10 authors, Toni K Choueiri.
J Clin Oncol, 2020 Oct 28; 38(36). PMID: 33108238    Free PMC article.
Heterogeneous Tumor-Immune Microenvironments between Primary and Metastatic Tumors in a Patient with ALK Rearrangement-Positive Large Cell Neuroendocrine Carcinoma.
Takahiro Tashiro, Kosuke Imamura, +10 authors, Takuro Sakagami.
Int J Mol Sci, 2020 Dec 24; 21(24). PMID: 33352665    Free PMC article.
Checkpoint inhibitor immunotherapy in kidney cancer.
Wenxin Xu, Michael B Atkins, David F McDermott.
Nat Rev Urol, 2020 Feb 06; 17(3). PMID: 32020040
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
Jeffrey A How, Amir Jazaeri, +10 authors, Aung Naing.
Invest New Drugs, 2021 Jan 09; 39(3). PMID: 33415580    Free PMC article.
Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks.
Giuseppe Fanciulli, Sergio Di Molfetta, +7 authors, Nike Group.
J Clin Med, 2021 Jan 02; 10(1). PMID: 33383673    Free PMC article.
Colon cancer and immunotherapy-can we go beyond microsatellite instability?
Rimini Breakstone.
Transl Gastroenterol Hepatol, 2021 Jan 08; 6. PMID: 33409406    Free PMC article.
Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma.
Bruce D Freimark, Jian Gong, +9 authors, Xianming Huang.
Cancer Immunol Res, 2016 Apr 06; 4(6). PMID: 27045021    Free PMC article.
Autologous cytokine-induced killer (CIK) cells enhance the clinical response to PD-1 blocking antibodies in patients with advanced non-small cell lung cancer: A preliminary study.
Ying Han, Di Mu, +8 authors, Xiubao Ren.
Thorac Cancer, 2020 Nov 06; 12(2). PMID: 33150733    Free PMC article.
Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.
Soheila Shirinbak, Randall Y Chan, +11 authors, Shahab Asgharzadeh.
Oncoimmunology, 2021 Jan 26; 10(1). PMID: 33489468    Free PMC article.
Current and future immunotherapy approaches in ovarian cancer.
Nazım Can Demircan, Stergios Boussios, Tolga Tasci, Mehmet Akif Öztürk.
Ann Transl Med, 2021 Jan 26; 8(24). PMID: 33490226    Free PMC article.
The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3.
Elly Marcq, Jonas R M Van Audenaerde, +5 authors, Evelien L J Smits.
Cancers (Basel), 2021 Jan 21; 13(2). PMID: 33466653    Free PMC article.
Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
Harry Cheuk Hay Lau, Joseph Jao-Yiu Sung, Jun Yu.
Gut Microbes, 2021 Jan 14; 13(1). PMID: 33435800    Free PMC article.
Oxidized Lipoproteins Promote Resistance to Cancer Immunotherapy Independent of Patient Obesity.
Niloufar Khojandi, Lindsey M Kuehm, +13 authors, Ryan M Teague.
Cancer Immunol Res, 2020 Dec 12; 9(2). PMID: 33303575    Free PMC article.
Complete response of hereditary leiomyomatosis and renal cell cancer (HLRCC)-associated renal cell carcinoma to nivolumab and ipilimumab combination immunotherapy by: a case report.
Yasuhiro Iribe, Mitsuko Furuya, +12 authors, Noboru Nakaigawa.
Fam Cancer, 2020 Jul 16; 20(1). PMID: 32666341
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma.
Catherine S Grasso, Jennifer Tsoi, +33 authors, Antoni Ribas.
Cancer Cell, 2020 Sep 12; 38(4). PMID: 32916126    Free PMC article.
Tailoring precision immunotherapy: coming to a clinic soon?
Shuting Han, Wai Ho Shuen, +2 authors, Han Chong Toh.
ESMO Open, 2021 Feb 10; 5 Suppl 1. PMID: 33558033    Free PMC article.
Novel Combination Therapies for the Treatment of Bladder Cancer.
Mei Peng, Di Xiao, +4 authors, Xiaoping Yang.
Front Oncol, 2021 Feb 16; 10. PMID: 33585182    Free PMC article.
Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors.
Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, +9 authors, Thomas Yau.
J Immunother Cancer, 2021 Feb 11; 9(2). PMID: 33563773    Free PMC article.
Emerging dynamics pathways of response and resistance to PD-1 and CTLA-4 blockade: tackling uncertainty by confronting complexity.
Allan Relecom, Maysaloun Merhi, +4 authors, Said Dermime.
J Exp Clin Cancer Res, 2021 Feb 20; 40(1). PMID: 33602280    Free PMC article.
Lipid signalling enforces functional specialization of Treg cells in tumours.
Seon Ah Lim, Jun Wei, +9 authors, Hongbo Chi.
Nature, 2021 Feb 26; 591(7849). PMID: 33627871    Free PMC article.
Associations of PD-L1, PD-L2, and HLA class I expression with responses to immunotherapy in patients with advanced sarcoma: post hoc analysis of a phase 1/2 trial.
S Miwa, T Nojima, +12 authors, H Tsuchiya.
Clin Transl Oncol, 2021 Feb 27; 23(8). PMID: 33635466
Efficacy of immune checkpoint inhibitors in different types of melanoma.
Ernesto Rossi, Giovanni Schinzari, +13 authors, Giampaolo Tortora.
Hum Vaccin Immunother, 2020 Jul 15; 17(1). PMID: 32663057    Free PMC article.
Methodology for in vitro Assessment of Human T Cell Activation and Blockade.
Joseph R Podojil, Igal Ifergan, +2 authors, Stephen D Miller.
Bio Protoc, 2021 Mar 05; 10(11). PMID: 33659314    Free PMC article.
Beyond immune checkpoint blockade: emerging immunological strategies.
Shawn P Kubli, Thorsten Berger, +2 authors, Tak W Mak.
Nat Rev Drug Discov, 2021 Mar 10; 20(12). PMID: 33686237
Current and Future Perspectives of PD-1/PDL-1 Blockade in Cancer Immunotherapy.
Rangarirai Makuku, Neda Khalili, +2 authors, Nima Rezaei.
J Immunol Res, 2021 Mar 09; 2021. PMID: 33681388    Free PMC article.
Results from a Meta-analysis of Combination of PD-1/PD-L1 and CTLA-4 Inhibitors in Malignant Cancer Patients: Does PD-L1 Matter?
Yuqian Feng, Huimin Jin, +5 authors, Shanming Ruan.
Front Pharmacol, 2021 Mar 16; 12. PMID: 33716732    Free PMC article.
Association of Survival and Immune-Related Adverse Events With Anti-PD-1/PD-L1 and Anti-CTLA-4 Inhibitors, Alone or Their Combination for the Treatment of Cancer: A Systematic Review and Meta-Analysis of 13 Clinical Trials.
Leyin Zhang, Leitao Sun, +5 authors, Shanming Ruan.
Front Oncol, 2021 Mar 16; 11. PMID: 33718135    Free PMC article.
Systematic Review.
A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies.
Philippe Armand, Alexander Lesokhin, +5 authors, Stephen M Ansell.
Leukemia, 2020 Jul 01; 35(3). PMID: 32601377    Free PMC article.
Clinical Significance of a Novel Tumor Progression-Associated Immune Signature in Colorectal Adenocarcinoma.
Rui Mao, Fan Yang, +4 authors, Tongtong Zhang.
Front Cell Dev Biol, 2021 Mar 19; 9. PMID: 33732694    Free PMC article.
The Multifaceted Role of Th1, Th9, and Th17 Cells in Immune Checkpoint Inhibition Therapy.
Jongdae Lee, Beatriz Lozano-Ruiz, +3 authors, Jose M González-Navajas.
Front Immunol, 2021 Mar 30; 12. PMID: 33777008    Free PMC article.
Bilateral murine tumor models for characterizing the response to immune checkpoint blockade.
Rachael M Zemek, Vanessa S Fear, +9 authors, W Joost Lesterhuis.
Nat Protoc, 2020 Apr 03; 15(5). PMID: 32238953
Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomas.
Maria Stella Sasso, Nikolaos Mitrousis, +5 authors, Melody A Swartz.
Sci Adv, 2021 Mar 26; 7(13). PMID: 33762337    Free PMC article.
Defining Immunogenic and Radioimmunogenic Tumors.
Terry R Medler, Tiffany C Blair, Marka R Crittenden, Michael J Gough.
Front Oncol, 2021 Apr 06; 11. PMID: 33816320    Free PMC article.
Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer.
Florus C de Jong, Vera C Rutten, Tahlita C M Zuiverloon, Dan Theodorescu.
Int J Mol Sci, 2021 Apr 04; 22(6). PMID: 33802033    Free PMC article.
Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance.
Marta Araujo-Castro, Eider Pascual-Corrales, Javier Molina-Cerrillo, Teresa Alonso-Gordoa.
Biomedicines, 2021 Apr 04; 9(3). PMID: 33809752    Free PMC article.
CD200 Immune-Checkpoint Peptide Elicits an Anti-glioma Response Through the DAP10 Signaling Pathway.
Elisabet Ampudia-Mesias, Francisco Puerta-Martinez, +9 authors, Michael R Olin.
Neurotherapeutics, 2021 Apr 09; 18(3). PMID: 33829411    Free PMC article.
A snapshot of the PD-1/PD-L1 pathway.
Chinmoy Ghosh, Gary Luong, Yue Sun.
J Cancer, 2021 Apr 16; 12(9). PMID: 33854633    Free PMC article.
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Brendan D Curti, Yoshinobu Koguchi, +17 authors, William L Redmond.
J Immunother Cancer, 2021 Apr 11; 9(4). PMID: 33837055    Free PMC article.
Immunotherapy for Prostate Cancer.
Nicholas J Venturini, Charles G Drake.
Cold Spring Harb Perspect Med, 2018 Sep 12; 9(5). PMID: 30201787    Free PMC article.
Systematic Assessment of Transcriptomic Biomarkers for Immune Checkpoint Blockade Response in Cancer Immunotherapy.
Shangqin Sun, Liwen Xu, +8 authors, Yun Xiao.
Cancers (Basel), 2021 May 01; 13(7). PMID: 33915876    Free PMC article.
Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC.
Yawen Dong, Jeffrey Sum Lung Wong, +7 authors, Thomas Yau.
Cancers (Basel), 2021 May 01; 13(8). PMID: 33919570    Free PMC article.
Immune Checkpoint Inhibitors: New Weapons Against Medullary Thyroid Cancer?
Sergio Di Molfetta, Andrea Dotto, +4 authors, Antongiulio Faggiano.
Front Endocrinol (Lausanne), 2021 May 04; 12. PMID: 33935977    Free PMC article.
Targeting Enclysis in Liver Autoimmunity, Transplantation, Viral Infection and Cancer.
Yara O Aghabi, Alia Yasin, +3 authors, Zania Stamataki.
Front Immunol, 2021 May 07; 12. PMID: 33953725    Free PMC article.
Development of a mechanism of action-reflective, dual target cell-based reporter bioassay for a bispecific monoclonal antibody targeting human CTLA-4 and PD-1.
Weimin Chen, Madhu Pandey, +7 authors, Shihua Lin.
MAbs, 2021 Apr 20; 13(1). PMID: 33870864    Free PMC article.
Nanobodies in cancer.
Elisha R Verhaar, Andrew W Woodham, Hidde L Ploegh.
Semin Immunol, 2020 Dec 05; 52. PMID: 33272897    Free PMC article.
Biologics and their delivery systems: Trends in myocardial infarction.
Matthew A Borrelli, Heth R Turnquist, Steven R Little.
Adv Drug Deliv Rev, 2021 Mar 30; 173. PMID: 33775706    Free PMC article.
Development of Immunotherapy Combination Strategies in Cancer.
Timothy A Yap, Eileen E Parkes, +3 authors, Hussein A Tawbi.
Cancer Discov, 2021 Apr 04; 11(6). PMID: 33811048    Free PMC article.
Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8+ T cells.
Kyung Soo Park, Jutaek Nam, Sejin Son, James J Moon.
Biomaterials, 2021 May 08; 274. PMID: 33962217    Free PMC article.
Combination Strategies to Augment Immune Check Point Inhibitors Efficacy - Implications for Translational Research.
Hrishi Varayathu, Vinu Sarathy, +2 authors, Radheshyam Naik.
Front Oncol, 2021 Jun 15; 11. PMID: 34123767    Free PMC article.
Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment.
Juan-Yan Liao, Shuang Zhang.
Front Oncol, 2021 Jun 15; 11. PMID: 34123821    Free PMC article.
B16 melanoma control by anti-PD-L1 requires CD8+ T cells and NK cells: application of anti-PD-L1 Abs and Trp2 peptide vaccines.
Sunhee Ji, Jaeyeon Lee, +2 authors, Jeong-Im Sin.
Hum Vaccin Immunother, 2021 Feb 02; 17(7). PMID: 33522416    Free PMC article.
Using oncolytic viruses to ignite the tumour immune microenvironment in bladder cancer.
Roger Li, Jingsong Zhang, +2 authors, James J Mulé.
Nat Rev Urol, 2021 Jun 30; 18(9). PMID: 34183833
Combination blockade of KLRG1 and PD-1 promotes immune control of local and disseminated cancers.
Angela Tata, Garvin Dodard, +5 authors, Laurent Brossay.
Oncoimmunology, 2021 Jul 01; 10(1). PMID: 34188973    Free PMC article.
Two Complementarity Immunotherapeutics in Non-Small-Cell Lung Cancer Patients-Mechanism of Action and Future Concepts.
Kamila Wojas-Krawczyk, Paweł Krawczyk, Michał Gil, Maciej Strzemski.
Cancers (Basel), 2021 Jul 03; 13(11). PMID: 34200219    Free PMC article.
Explant Modeling of the Immune Environment of Head and Neck Cancer.
Shay Sharon, Thomas Duhen, +9 authors, Michael Gough.
Front Oncol, 2021 Jul 06; 11. PMID: 34221953    Free PMC article.
Low-Dose Radiation Potentiates the Propagation of Anti-Tumor Immunity against Melanoma Tumor in the Brain after In Situ Vaccination at a Tumor outside the Brain.
Paul A Clark, Raghava N Sriramaneni, +17 authors, Zachary S Morris.
Radiat Res, 2021 Apr 08; 195(6). PMID: 33826741    Free PMC article.
Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners.
Marek Z Wojtukiewicz, Magdalena M Rek, +7 authors, Kenneth V Honn.
Cancer Metastasis Rev, 2021 Jul 09; 40(3). PMID: 34236546    Free PMC article.
Metabolism-Relevant Molecular Classification Identifies Tumor Immune Microenvironment Characterization and Immunotherapeutic Effect in Cervical Cancer.
Luyi Li, Hui Gao, +5 authors, Changjiang Huang.
Front Mol Biosci, 2021 Jul 20; 8. PMID: 34277697    Free PMC article.
Pulsed focused ultrasound can improve the anti-cancer effects of immune checkpoint inhibitors in murine pancreatic cancer.
Petros X E Mouratidis, Marcia Costa, +2 authors, Gail Ter Haar.
J R Soc Interface, 2021 Jul 08; 18(180). PMID: 34229458    Free PMC article.
Perioperative Systemic Treatment for Muscle-Invasive Bladder Cancer: Current Evidence and Future Perspectives.
In-Ho Kim, Hyo-Jin Lee.
Int J Mol Sci, 2021 Jul 21; 22(13). PMID: 34281253    Free PMC article.
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.
Espen Basmo Ellingsen, Sara M Mangsbo, Eivind Hovig, Gustav Gaudernack.
Front Immunol, 2021 Jul 23; 12. PMID: 34290704    Free PMC article.
Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.
Aaron C Tan, Stephen J Bagley, +18 authors, Mustafa Khasraw.
J Immunother Cancer, 2021 Jul 04; 9(7). PMID: 34215688    Free PMC article.
Systematic Review.
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies.
Ryan J Sullivan, Jeffrey S Weber.
Nat Rev Drug Discov, 2021 Jul 29;. PMID: 34316029
A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment.
A Farias, A Soto, +5 authors, P M Berguer.
Sci Rep, 2021 Jul 30; 11(1). PMID: 34321536    Free PMC article.
CARM1 Inhibition Enables Immunotherapy of Resistant Tumors by Dual Action on Tumor Cells and T Cells.
Sushil Kumar, Zexian Zeng, +19 authors, Kai W Wucherpfennig.
Cancer Discov, 2021 Mar 13; 11(8). PMID: 33707234    Free PMC article.
[Research Progress of Adverse Events Related to PD-1/PD-L1 Inhibitors 
Based Combination Therapy].
Xiaoyu Guo, Ti Wen, Xiujuan Qu.
Zhongguo Fei Ai Za Zhi, 2021 Jul 20; 24(7). PMID: 34275517    Free PMC article.
Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.
Renata Ferrarotto, Diana Bell, +16 authors, Neil D Gross.
Clin Cancer Res, 2020 Apr 10; 26(13). PMID: 32269052    Free PMC article.
Characterization of neoantigen-specific T cells in cancer resistant to immune checkpoint therapies.
Shamin Li, Yannick Simoni, +10 authors, Evan W Newell.
Proc Natl Acad Sci U S A, 2021 Jul 22; 118(30). PMID: 34285073    Free PMC article.
Immune mechanisms orchestrate tertiary lymphoid structures in tumors via cancer-associated fibroblasts.
Anthony B Rodriguez, J David Peske, +12 authors, Victor H Engelhard.
Cell Rep, 2021 Jul 22; 36(3). PMID: 34289373    Free PMC article.
Current and future drug combination strategies based on programmed death-1/programmed death-ligand 1 inhibitors in non-small cell lung cancer.
Ying Cheng, Hui Li, +3 authors, Shuang Zhang.
Chin Med J (Engl), 2021 Jun 17; 134(15). PMID: 34133356    Free PMC article.
Implantable optical fibers for immunotherapeutics delivery and tumor impedance measurement.
Ai Lin Chin, Shan Jiang, +4 authors, Rong Tong.
Nat Commun, 2021 Aug 28; 12(1). PMID: 34446702    Free PMC article.
Vascular Normalization: A New Window Opened for Cancer Therapies.
Ting Yang, Hongqi Xiao, +4 authors, Xinggang Guo.
Front Oncol, 2021 Sep 04; 11. PMID: 34476218    Free PMC article.
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Natasha B Leighl, Mary W Redman, +16 authors, David R Gandara.
J Immunother Cancer, 2021 Aug 26; 9(8). PMID: 34429332    Free PMC article.
Identification of Immune Cell Infiltration Landscape and Their Prognostic Significance in Uveal Melanoma.
Han Zhao, Yun Chen, Peijun Shen, Lan Gong.
Front Cell Dev Biol, 2021 Sep 14; 9. PMID: 34513843    Free PMC article.
Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
Sho Isoyama, Shigeyuki Mori, +6 authors, Hiroyoshi Nishikawa.
J Immunother Cancer, 2021 Aug 28; 9(8). PMID: 34446575    Free PMC article.
New approaches to first-line treatment of advanced renal cell carcinoma.
Daniel J George, Chung-Han Lee, Daniel Heng.
Ther Adv Med Oncol, 2021 Sep 17; 13. PMID: 34527080    Free PMC article.
Evaluating prognostic value and relevant gene signatures of tumor microenvironment characterization in esophageal carcinoma.
Wang Sheng, Xiaoyu Li, +2 authors, Fan Li.
J Gastrointest Oncol, 2021 Sep 18; 12(4). PMID: 34532083    Free PMC article.
A new approach to produce IgG4-like bispecific antibodies.
Caizhi Zhao, Wei Zhang, +3 authors, Youjia Hu.
Sci Rep, 2021 Sep 22; 11(1). PMID: 34545109    Free PMC article.
Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR.
Nicholas L Bayless, Jeffrey A Bluestone, +8 authors, Theresa L Walunas.
J Immunother Cancer, 2021 Sep 05; 9(9). PMID: 34479924    Free PMC article.
High-salt diet mediates interplay between NK cells and gut microbiota to induce potent tumor immunity.
Zaigham Abbas Rizvi, Rajdeep Dalal, +6 authors, Amit Awasthi.
Sci Adv, 2021 Sep 14; 7(37). PMID: 34516769    Free PMC article.
Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy.
Hirofumi Shibata, Shin Saito, Ravindra Uppaluri.
Front Oncol, 2021 Sep 24; 11. PMID: 34552878    Free PMC article.
Metavariables Resuming Host Immune Features and Nodal Involvement Are Associated with Oncological Outcomes in Oral Cavity Squamous Cell Carcinoma.
Francesco Missale, Mattia Bugatti, +8 authors, William Vermi.
Cells, 2021 Sep 29; 10(9). PMID: 34571850    Free PMC article.
Improving Biologics' Effectiveness in Clinical Oncology: From the Combination of Two Monoclonal Antibodies to Oligoclonal Antibody Mixtures.
Christel Larbouret, Laurent Gros, André Pèlegrin, Thierry Chardès.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572847    Free PMC article.
Adoptive cell therapy with tumor-infiltrating lymphocytes supported by checkpoint inhibition across multiple solid cancer types.
Anders Handrup Kverneland, Christopher Aled Chamberlain, +10 authors, Inge Marie Svane.
J Immunother Cancer, 2021 Oct 06; 9(10). PMID: 34607899    Free PMC article.
AMPK promotes antitumor immunity by downregulating PD-1 in regulatory T cells via the HMGCR/p38 signaling pathway.
Ram Hari Pokhrel, Suman Acharya, +7 authors, Jae-Hoon Chang.
Mol Cancer, 2021 Oct 16; 20(1). PMID: 34649584    Free PMC article.
Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.
Emily Nickles, Bhushan Dharmadhikari, +26 authors, Herbert Schwarz.
Cancer Immunol Immunother, 2021 Oct 19; 71(6). PMID: 34661709
Immunosuppressive metabolites in tumoral immune evasion: redundancies, clinical efforts, and pathways forward.
Maria Rain Jennings, David Munn, John Blazeck.
J Immunother Cancer, 2021 Oct 21; 9(10). PMID: 34667078    Free PMC article.
T cell exhaustion drives osteosarcoma pathogenesis.
Cheng-Ying Sun, Zhe Zhang, +4 authors, Wei Liu.
Ann Transl Med, 2021 Nov 05; 9(18). PMID: 34733999    Free PMC article.
Exosome CTLA-4 Regulates PTEN/CD44 Signal Pathway in Spleen Deficiency Internal Environment to Promote Invasion and Metastasis of Hepatocellular Carcinoma.
Yongdan Wang, Pan Li, +7 authors, Ling Yu.
Front Pharmacol, 2021 Nov 09; 12. PMID: 34744733    Free PMC article.
Intratumoral DNA-based delivery of checkpoint-inhibiting antibodies and interleukin 12 triggers T cell infiltration and anti-tumor response.
Liesl Jacobs, Lidia Yshii, +4 authors, Paul Declerck.
Cancer Gene Ther, 2021 Nov 11;. PMID: 34754076
Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors.
Yu-Chao Zhu, Hany M Elsheikha, +4 authors, Jia Chen.
J Immunother Cancer, 2021 Nov 03; 9(11). PMID: 34725213    Free PMC article.
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in Braf-mutated melanoma.
Michael G White, Robert Szczepaniak Sloane, +29 authors, Jennifer A Wargo.
Oncoimmunology, 2021 Nov 16; 10(1). PMID: 34777916    Free PMC article.
Postoperative Natural Killer Cell Dysfunction: The Prime Suspect in the Case of Metastasis Following Curative Cancer Surgery.
Marisa Market, Gayashan Tennakoon, Rebecca C Auer.
Int J Mol Sci, 2021 Nov 14; 22(21). PMID: 34768810    Free PMC article.
MK-6, a novel not-α IL-2, elicits a potent antitumor activity by improving the effector to regulatory T cell balance.
Maki Kobayashi, Katsuhiko Kojima, +6 authors, Nobuyuki Tanaka.
Cancer Sci, 2021 Sep 22; 112(11). PMID: 34545658    Free PMC article.
Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling.
Qian Jiang, Nan Zhang, +3 authors, Lei Liu.
Cancer Manag Res, 2021 Nov 20; 13. PMID: 34795530    Free PMC article.
Pyroptosis-related gene mediated modification patterns and immune cell infiltration landscapes in cutaneous melanoma to aid immunotherapy.
Jinzhi Meng, Xing Huang, +4 authors, Jun Yao.
Aging (Albany NY), 2021 Nov 11; 13(21). PMID: 34753832    Free PMC article.
Identification of Genes Potentially Associated with Melanoma Tumorigenesis Through Co-Expression Network Analysis.
Xiuyun Xuan, Yuqi Wang, Yanhong Sun, Changzheng Huang.
Int J Gen Med, 2021 Nov 27; 14. PMID: 34824546    Free PMC article.
Bridging Radiotherapy to Immunotherapy: The IFN-JAK-STAT Axis.
Lewis Zhichang Shi, James A Bonner.
Int J Mol Sci, 2021 Nov 28; 22(22). PMID: 34830176    Free PMC article.
Systematic Review.
The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10-IL-10R Pathways in Acute Myeloid Leukemia.
Laura Jimbu, Oana Mesaros, +5 authors, Mihnea Zdrenghea.
Pharmaceuticals (Basel), 2021 Nov 28; 14(11). PMID: 34832887    Free PMC article.
IFNγ induces JAK1/STAT1/p65 NFκB-dependent interleukin-8 expression in ovarian cancer cells, resulting in their increased migration.
Sveta Padmanabhan, Bijaya Gaire, +3 authors, Ivana Vancurova.
Int J Biochem Cell Biol, 2021 Oct 10; 141. PMID: 34626802    Free PMC article.
Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges.
Zhitao Li, Guoqiang Sun, +7 authors, Weiwei Tang.
Front Oncol, 2021 Dec 07; 11. PMID: 34869005    Free PMC article.
Immunotherapy of cancer in the era of checkpoint inhibitor.
Inderjit Mehmi, Omid Hamid.
Clin Exp Metastasis, 2021 Dec 09; 39(1). PMID: 34878618
Identification and Construction of a Predictive Immune-Related lncRNA Signature Model for Melanoma.
Fang-Wei Li, Sheng-Kang Luo.
Int J Gen Med, 2021 Dec 10; 14. PMID: 34880662    Free PMC article.
CD73-Mediated Immunosuppression Is Linked to a Specific Fibroblast Population That Paves the Way for New Therapy in Breast Cancer.
Ilaria Magagna, Nicolas Gourdin, +7 authors, Fatima Mechta-Grigoriou.
Cancers (Basel), 2021 Dec 11; 13(23). PMID: 34884993    Free PMC article.
Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy.
Shiyan Yang, Yajun Cheng, +3 authors, Shanzhong Tan.
Front Genet, 2021 Dec 14; 12. PMID: 34899862    Free PMC article.
Current Progress and Future Perspectives of Immune Checkpoint in Cancer and Infectious Diseases.
Xin Cai, Huajie Zhan, +4 authors, Yuan Zhuang.
Front Genet, 2021 Dec 18; 12. PMID: 34917131    Free PMC article.
Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer.
Xuan Lin, Hedan Chen, +9 authors, Lina Liu.
Transl Oncol, 2021 Dec 08; 15(1). PMID: 34875483    Free PMC article.
The foundations of immune checkpoint blockade and the ipilimumab approval decennial.
Alan J Korman, Sarah C Garrett-Thomson, Nils Lonberg.
Nat Rev Drug Discov, 2021 Dec 24;. PMID: 34937915
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer.
Chang Gon Kim, Gamin Kim, +8 authors, Hye Ryun Kim.
J Immunother Cancer, 2021 Dec 16; 9(12). PMID: 34907028    Free PMC article.
Immunotherapy Resistance in Glioblastoma.
Elaina J Wang, Jia-Shu Chen, +5 authors, Manish K Aghi.
Front Genet, 2022 Jan 04; 12. PMID: 34976006    Free PMC article.
Interleukin-2, Ipilimumab, and Anti-PD-1: clinical management and the evolving role of immunotherapy for the treatment of patients with metastatic melanoma.
Tasha Hughes, Matthew Klairmont, William H Sharfman, Howard L Kaufman.
Cancer Biol Ther, 2015 Sep 30; 22(10-12). PMID: 26418961    Free PMC article.
Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.
Dixita Ishani Viswanath, Hsuan-Chen Liu, +2 authors, Alessandro Grattoni.
Biomaterials, 2021 Dec 14; 280. PMID: 34902729    Free PMC article.
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Jonas Bochem, Henning Zelba, +20 authors, Kilian Wistuba-Hamprecht.
J Immunother Cancer, 2021 Dec 23; 9(12). PMID: 34933966    Free PMC article.
Landscape and Clinical Significance of Immune Checkpoint in Cutaneous Melanoma.
Rui Mao, Fan Yang, Tongtong Zhang, Ji Li.
Front Immunol, 2022 Jan 11; 12. PMID: 35003069    Free PMC article.
Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.
Miranda C Lahman, Kelly G Paulson, Paul T Nghiem, Aude G Chapuis.
J Invest Dermatol, 2021 Apr 18; 141(8). PMID: 33863500    Free PMC article.
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade.
Golnaz Morad, Beth A Helmink, Padmanee Sharma, Jennifer A Wargo.
Cell, 2021 Oct 09; 184(21). PMID: 34624224    Free PMC article.
T cells in pancreatic cancer stroma.
Michelle R Goulart, Konstantinos Stasinos, +2 authors, Hemant M Kocher.
World J Gastroenterol, 2022 Jan 21; 27(46). PMID: 35046623    Free PMC article.
Immunotherapy combinations and chemotherapy sparing schemes in first line non-small cell lung cancer.
María Sereno, Oliver Higuera, +4 authors, Felipe Couñago.
World J Clin Oncol, 2022 Jan 25; 12(12). PMID: 35070737    Free PMC article.
Potentiality of α-fetoprotein (AFP) and soluble intercellular adhesion molecule-1 (sICAM-1) in prognosis prediction and immunotherapy response for patients with hepatocellular carcinoma.
Weiwei Cao, Yu Chen, +6 authors, Xiao Li.
Bioengineered, 2021 Oct 27; 12(2). PMID: 34696675    Free PMC article.
Identification of Epithelial Mesenchymal Transition-Related lncRNAs Associated with Prognosis and Tumor Immune Microenvironment of Hepatocellular Carcinoma.
Yongjie Zhou, Liangwen Wang, +6 authors, Zhiping Yan.
Dis Markers, 2022 Feb 04; 2022. PMID: 35111268    Free PMC article.
Effective management of advanced colon cancer genotyping microsatellite stable/microsatellite instable-low with Kirsten rat sarcoma viral oncogene mutation using nivolumab plus ipilimumab combined with regorafenib and irinotecan: A case report.
Yingqiang Cui, Yimeng Ou, +3 authors, Size Chen.
SAGE Open Med Case Rep, 2022 Feb 15; 9. PMID: 35154775    Free PMC article.
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.
Adrià Archilla-Ortega, Carla Domuro, Juan Martin-Liberal, Purificación Muñoz.
J Exp Clin Cancer Res, 2022 Feb 16; 41(1). PMID: 35164813    Free PMC article.
PD-1 and TIGIT downregulation distinctly affect the effector and early memory phenotypes of CD19-targeting CAR T cells.
Young-Ho Lee, Hyeong Ji Lee, +11 authors, Chan Hyuk Kim.
Mol Ther, 2021 Oct 11; 30(2). PMID: 34628052    Free PMC article.
Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?
Sergio Di Molfetta, Tiziana Feola, +4 authors, Nike Group.
J Clin Med, 2022 Feb 26; 11(4). PMID: 35207291    Free PMC article.
An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity.
Xuedan He, Shiqi Zhou, +5 authors, Jonathan F Lovell.
Cancer Immunol Res, 2022 Jan 08; 10(3). PMID: 34992135    Free PMC article.
FAT10 is a Prognostic Biomarker and Correlated With Immune Infiltrates in Skin Cutaneous Melanoma.
Yu Wang, Haiyue Zhang.
Front Mol Biosci, 2022 Mar 19; 9. PMID: 35300113    Free PMC article.
Addressing the Elephant in the Immunotherapy Room: Effector T-Cell Priming versus Depletion of Regulatory T-Cells by Anti-CTLA-4 Therapy.
Megan M Y Hong, Saman Maleki Vareki.
Cancers (Basel), 2022 Mar 26; 14(6). PMID: 35326731    Free PMC article.
Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development.
Xiyun Xiao, Saitian Zeng, +2 authors, Jiyan Zhang.
J Oncol, 2022 Apr 09; 2022. PMID: 35392432    Free PMC article.
Understanding of Immune Escape Mechanisms and Advances in Cancer Immunotherapy.
Nasrin Aktar, Chen Yueting, +7 authors, Xiaohui Zhou.
J Oncol, 2022 Apr 12; 2022. PMID: 35401745    Free PMC article.
OCT4 and SOX2 Specific Cytotoxic T Cells Exhibit Not Only Good Efficiency but Also Synergize PD-1 Inhibitor (Nivolumab) in Treating Breast Cancer Stem-Like Cells and Drug-Resistant Breast Cancer Mice.
Wei Peng, Liang Chang, +2 authors, Min Zhang.
Front Oncol, 2022 Apr 12; 12. PMID: 35402219    Free PMC article.
Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy.
Sang T Kim, Yanshuo Chu, +35 authors, Roza Nurieva.
Nat Commun, 2022 Apr 14; 13(1). PMID: 35413951    Free PMC article.
Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses?
Michael Kuske, Maximilian Haist, +2 authors, Matthias Bros.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406483    Free PMC article.
Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers.
Sandra Kang, Bassel F El-Rayes, Mehmet Akce.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406520    Free PMC article.
Inducible Co-Stimulator ICOS Expression Correlates with Immune Cell Infiltration and Can Predict Prognosis in Lung Adenocarcinoma.
Gujie Wu, Min He, +2 authors, Qun Xue.
Int J Gen Med, 2022 Apr 15; 15. PMID: 35418779    Free PMC article.
A Monoclonal Anti-HMGB1 Antibody Attenuates Neurodegeneration in an Experimental Animal Model of Glaucoma.
Henrik Tonner, Selina Hunn, +5 authors, Franz H Grus.
Int J Mol Sci, 2022 Apr 24; 23(8). PMID: 35456925    Free PMC article.
Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy.
Douglas S Jones, Jonathan D Nardozzi, +11 authors, Thomas L Andresen.
Sci Adv, 2022 Apr 28; 8(17). PMID: 35476449    Free PMC article.
A Novel Risk Score Model Based on Eleven Extracellular Matrix-Related Genes for Predicting Overall Survival of Glioma Patients.
Xiaodong Li, Yichang Wang, +5 authors, Hai Yu.
J Oncol, 2022 May 10; 2022. PMID: 35528238    Free PMC article.
Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade.
Min Zhang, Kehai Liu, Mingfu Wang.
RSC Adv, 2019 Oct 22; 9(58). PMID: 35528929    Free PMC article.
Programmed Death-Ligand 1 (PD-L1) Positivity and Factors Associated with Poor Prognosis in Patients with Gastric Cancer: An Umbrella Meta-Analysis.
Gashaw Hassen, Amita Kasar, +12 authors, Rishabh K Rana.
Cureus, 2022 May 10; 14(4). PMID: 35530821    Free PMC article.
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue.
Zhi Li, Zewen K Tuong, +16 authors, David R Withers.
J Exp Med, 2022 Apr 27; 219(6). PMID: 35472220    Free PMC article.
Prognostic Value and Therapeutic Perspectives of CXCR Members in the Glioma Microenvironment.
Jiarong He, Zhongzhong Jiang, +4 authors, Mingming Zhang.
Front Genet, 2022 May 17; 13. PMID: 35571062    Free PMC article.
Exosomes in cancer immunoediting and immunotherapy.
Yarong Zhao, Luotong Liu, +6 authors, Lesheng Teng.
Asian J Pharm Sci, 2022 May 19; 17(2). PMID: 35582642    Free PMC article.
Molecular characteristics of novel immune subtypes of HCC based on lncRNAs related to immune disorders.
Qiyao Zhang, Xiao Yu, +2 authors, Yuting He.
Sci Rep, 2022 May 27; 12(1). PMID: 35618810
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities.
Tae Kon Kim, Esten N Vandsemb, Roy S Herbst, Lieping Chen.
Nat Rev Drug Discov, 2022 Jun 15;. PMID: 35701637